



CHEST *Physician*

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



JOHN MCCULLY/UNIVERSITY OF PITTSBURGH MEDICAL CENTER

Hospital blood management programs are a growing phenomenon, said Dr. Jonathan Waters of the University of Pittsburgh.

Blood Costs, Benefits Are a Delicate Balance

BY MICHELE G. SULLIVAN

Elsevier Global Medical News

Faced with skyrocketing costs, a dwindling supply, and ever-increasing demand, hospitals are finding ways to optimally manage one of their most precious resources—blood.

“The supply of blood in this country is decreasing as the need continues to rise,” said Dr. Ajay Kumar, medical director of blood management at the Cleveland Clinic. It’s a perfect storm of sorts, he said in an interview. “We’re operating more, doing more complex surgery, and our patients consist of a larger pool of the aging population. There

is a projected deficit of blood by 2030—and it looks like it will be quite an imbalance, with a shortage of up to 4 million units per year.”

But the looming shortfall is just one prod for hospitals to re-examine their blood use policies.

Although most blood comes from free donation, it’s not cheap to store it, keep track of it, or use it. And there’s no denying that blood transfusion exposes patients to a unique set of health risks, said Deborah Tolich, R.N., regional director for blood management at the Cleveland Clinic.

Immunomodulation is probably the most significant of

See **Blood Costs** • page 4

FDA Panels: ‘No’ to LABA Monotherapy, ‘Yes’ to Combo Tx

Use of LABAs for asthma debated.

BY ELIZABETH MECHCATIE

Elsevier Global Medical News

ROCKVILLE, MD. — The benefits of the single-ingredient, long-acting β -agonist products salmeterol (Serevent) and formoterol (Foradil) do not outweigh their risks when used for treating asthma in adults, adolescents, and children, according to a majority of the three Food and Drug Administration advisory panels who reviewed the safety of the drugs.

However, most of the panelists at the joint meeting Dec. 10-11 of the FDA’s Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and Pediatric Advisory Committee agreed that the benefits of Advair, which combines salmeterol with the inhaled corticosteroid (ICS) fluticasone, and Symbicort,

which combines formoterol with the ICS budesonide, outweighed the risks when used to treat asthma in adults and adolescents.

The panel members recommended that safety be further studied in randomized, controlled trials; that health care practitioners and patients be educated about the importance of an ICS as a first-line treatment for asthma; and that a long-acting β -agonist (LABA) always be combined with an ICS. The FDA usually follows the recommendations of its advisory panels, which are not binding.

The three committees met to review the risks and benefits of the four inhaled LABAs marketed in the United States for adults and children with asthma. The committees also discussed whether the drugs

See **Monotherapy** • page 5

INSIDE

News

Aging Pressure

An age-associated rise in pulmonary artery systolic pressure was linked to an increased risk of death. • 3

Pulmonary Medicine

LABA Safety

Dr. Jay Peters outlines the implications of the recent FDA committees’ hearing on LABAs for asthma. • 5

Sleep Institute[®]

American College of Chest Physicians

News From the College

Sleep Strategies

How will CMS’ approval of reimbursement for home sleep apnea testing affect sleep medicine? • 8

Pediatric Chest Medicine


Asthma Relief

Treating GERD in children with persistent asthma improved lung function in the long term. • 15

VITAL SIGNS

Number of People per Active Physician By Specialty, 2007

(In thousands)



Source: 2008 Physician Specialty Data, Association of American Medical Colleges

ELSEVIER GLOBAL MEDICAL NEWS

OSA Is Common in Post-MI Patients

BY BRUCE JANCIN

Elsevier Global Medical News

NEW ORLEANS — Obstructive sleep apnea is common in patients who have recently had a myocardial infarction and is closely linked to the presence of complex ventricular arrhythmias.

These findings from an Italian observational study have two important implications worthy of further investigation, Dr. Stefano Fumagalli said at the annual scientific sessions of the American Heart Association.

One possibility raised by the study is that continuous positive airway pressure for the treatment of obstructive sleep apnea (OSA) in affected patients post MI might improve

cardiovascular outcomes. The other potential implication is that an evaluation for OSA might prove useful in deciding whether to place an implantable cardioverter-defibrillator in a patient with a reduced left ventricular ejection fraction post MI, according to Dr. Fumagalli of the University of Florence (Italy).

He reported on 107 consecutive patients who underwent

sleep studies 1 month following acute MIs. Seventy-six percent of patients had primary percutaneous coronary intervention for their MI, which was an ST-elevation MI in more than two-thirds of study participants. Men composed 83% of the consecutive patient series. Participants’ mean body weight was 78 kg.

See **Post-MI** • page 2

CHEST PHYSICIAN
60 Columbia Rd., Bldg. B
Morristown, NJ 07960
CHANGE SERVICE REQUESTED

Presorted Standard
U.S. Postage
PAID
Permit No. 384
Lebanon Jct. KY

CHEST Physician Adds to Its Editorial Team

It is with pleasure that we welcome the following ACCP members filling CHEST PHYSICIAN positions:

New Editor in Chief

► **Dr. Paul A. Selecky, FCCP**, has assumed the position of editor in chief. Dr. Selecky served as deputy editor and is a 2-year veteran of the newspaper's editorial advisory board. He is clinical professor of medicine at UCLA; and medical director of the Pulmonary Department, Sleep Disorders Center, and Palliative Medicine Service, Hoag Hospital, Newport Beach, Calif. Dr. Selecky is a past chair of the ACCP Continuing Education Committee and a past president of NAMDRM. He has participated in ACCP committees, including Ethics, Government Relations, and Health and Science Policy. He is a past chair of the Respiratory Care NetWork.



DR. SELECKY

► **Dr. Neil Halpern, FCCP**, has assumed the position of section editor for Critical Care Commentary. Dr. Halpern is currently chief of critical care medicine and medical director of respiratory therapy at the Memorial Sloan-Kettering Cancer Center, New York, and is professor of medicine and anesthesiology at the Weill Medical College of Cornell University, New York. He is a Fellow of the ACCP. Dr. Halpern is a prolific author and noted speaker, specializing in cost and use of critical care in America, technology introduction in critical care, and innovations in ICU design.



DR. HALPERN

► **Dr. James Parish, FCCP**, has assumed the position of section editor for Sleep Strategies. Dr. Parish is currently chair of the Division of Pulmonary Medicine and associate professor of medicine at Mayo Clinic College of Medicine in Scottsdale, Ariz. He is board-certified in internal medicine, pulmonary medicine, and sleep medicine through the American Board of Internal Medicine. He is a Fellow of the ACCP, a member of the ACCP Sleep Institute, and on the steering committee of the ACCP Sleep Medicine NetWork. Dr. Parish has served as chair of the ACCP Government Relations Committee and ACCP Governor for Arizona.



DR. PARISH

► **Dr. Richard Fischel, FCCP**, is currently the director of thoracic oncology at Hoag Hospital in Newport Beach, Calif. He is chief of surgery and director of the Lung Center at Chapman Medical Center, a Medicare-approved lung volume reduction surgery site. He is a board-certified general thoracic surgeon specializing in minimally invasive thoracic surgery. Dr. Fischel also serves as the president of the Orange County Board of the American Lung Association. He received a PhD in surgery and immunology at the University of Minnesota for his work in the field of xenotransplantation.

New Editorial Advisory Board Members

► **Dr. Burt Lesnick, FCCP**, is a practicing pediatric pulmonologist in Atlanta, where he is managing partner of Georgia Pediatric Pulmonology Associates, a group of 11 pediatric pulmonologists. He also serves as chief of the Department of Medicine for Children's Healthcare of Atlanta. Dr. Lesnick is a Fellow of the ACCP and serves the ACCP as vice-chair of the Pediatric Chest Medicine NetWork, steering committee member of the Private Practice NetWork, and member of the Practice Management Committee. He is the alternate ACCP representative to the AMA RUC (RBRVS Update Committee).

► **Dr. Nirupam Singh** is practicing full-time critical care at Hoag Hospital in Newport Beach, Calif. After finishing medical school with the University of Delhi in India, Dr. Singh did his residency at Upstate Medical Center in Syracuse, N.Y. He subsequently finished fellowship training in pulmonary and critical care at Tufts/New England Medical Center in Boston. Dr. Singh's areas of interest include hypothermia after cardiac arrest and patient ventilator synchrony.

Sleep Apnea

Post-MI • from page 1

The mean apnea-hypopnea index (AHI) was 14.3 events/hr. A normal AHI—that is, a value less than 5—was present in only 26% of patients. Some 40% percent of participants had an AHI greater than 15, indicative of OSA of at least moderate severity.

Fifty-two patients had complex ventricular arrhythmias on 24-hour Holter monitoring. Their mean AHI was 16.8, significantly greater than the AHI of 12.2 in patients without complex ventricular arrhythmias.

In a multivariate regression analysis, the strongest predictor of OSA was the presence of complex ventricular arrhythmias, which conferred a 5.8-fold increased risk. Other independent predictors of OSA were an increased serum creatinine, the presence of aortic insufficiency, and greater body weight.

Dr. Fumagalli noted that, although OSA previously has been linked to hypertension, atrial fibrillation, and heart failure, there have been few prior studies investigating a possible association with ischemic heart disease. ■

Dr. Stephen A. Geraci, FCCP, comments: *Scientifically, I would bet that many—if not most—patients had OSA before their MI, and that many had heart failure before and/or after. Some percentage of sudden death is likely from infarction, though a concept exceedingly difficult to prove. In a perfect world, we would pick up the OSA before their MI, as it is no great stretch to see a relationship between the sympathetic activation causing plaque destabilization and MI. It is likely that nobody's algorithm has "sleep study" on the post-MI order set. This doesn't say that we should, but it alerts people to the possibility.*

IN THIS ISSUE

News From the College • 6

Practice Management

Find out the overall impact that this year's changes to the Medicare physician fee schedule will have on pulmonary medicine. • 6

CHEST PHYSICIAN Is Online

CHEST PHYSICIAN is available on the Web at www.chestnet.org/about/publications.

AMERICAN COLLEGE OF CHEST PHYSICIAN S

AMERICAN COLLEGE OF CHEST PHYSICIANS

Editor in Chief Paul A. Selecky, M.D., FCCP
President James A. L. Mathers, Jr., M.D., FCCP
Executive Vice President and CEO Alvin Lever, MA, FCCP(Hon)
Vice President, Publications Stephen J. Welch
Assistant Vice President, Editorial Resources Pamela L. Goorsky
Medical Copy Editor Peggy Eastmond, R.D.
Section Editors
 Neil Halpern, M.D., FCCP - **Critical Care Commentary**
 James Parish, M.D., FCCP - **Sleep Strategies**

EDITORIAL ADVISORY BOARD

Doreen Addrizzo-Harris, M.D., FCCP, New York
 W. Michael Alberts, M.D., FCCP, Florida
 Richard Fischel, M.D., FCCP, California
 Stephen A. Geraci, M.D., FCCP, Mississippi
 Nicola A. Hanania, M.D., FCCP, Texas
 Burt Lesnick, M.D., FCCP, Georgia
 Philip Marcus, M.D., FCCP, New York
 Mark L. Metersky, M.D., FCCP, Connecticut
 Stephen M. Pastores, M.D., FCCP, New York
 Nirupam Singh, M.D., California
 Keith M. Wille, M.D., FCCP, Alabama

E-mail: chestphysiciannews@chestnet.org

CHEST PHYSICIAN

CHEST PHYSICIAN, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to the members of the American College of Chest Physicians. Content for CHEST PHYSICIAN is provided by International Medical News Group and Elsevier Global Medical News. Content for NEWS FROM THE COLLEGE is provided by the American College of Chest Physicians.

The statements and opinions expressed in CHEST PHYSICIAN do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Elsevier Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

Address Changes: Fax changes of address (with old mailing label) to 973-290-8245.


POSTMASTER: Send change of address (with old mailing label) to CHEST PHYSICIAN, 60 B Columbia Rd., 2nd fl., Morristown, NJ 07960.

CHEST PHYSICIAN (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Elsevier Inc., 60 B Columbia Rd., 2nd fl., Morristown, NJ 07960, 973-290-8200, fax 973-290-8250.

©Copyright 2009, by the American College of Chest Physicians

ELSEVIER SOCIETY NEWS GROUP, A DIVISION OF INTERNATIONAL MEDICAL NEWS GROUP

President, IMNG Alan J. Imhoff
Director, ESNG Mark Branca
Executive Director, Editorial Mary Jo M. Dales
Executive Editor, IMNG Denise Fulton
Executive Editor, EGMM Kathy Scarbeck
Publication Editor Terry Rudd
Publication Associate Editor Jay C. Cherniak
VP, Medical Education Sylvia H. Reitman
Senior Director, Marketing and Research Janice Theobald
Circulation Analyst Barbara Cavallaro, 973-290-8253, b.cavallaro@elsevier.com
Executive Director, Operations Jim Chicca
Director, Production and Manufacturing Yvonne Evans
Production Manager Judi Sheffer
Creative Director Louise A. Koenig
Display Advertising Manager The Walchli Tauber Group: 443-512-8899, fax 443-512-8909, gary.walchli@wt-group.com, stephen.tauber@wt-group.com, greg.pessagno@wt-group.com
Classified Sales Manager Rhonda Beamer, 443-512-8899, fax 443-512-8909, rhonda.beamer@wt-group.com
ADVERTISING OFFICES 60 B Columbia Rd., 2nd fl., Morristown, NJ 07960, 973-290-8200, fax 973-290-8250
CLASSIFIED ADVERTISING OFFICES The Walchli Tauber Group, 2225 Old Emmorton Rd., Suite 201, Bel Air, MD 21015, 443-512-8899
EDITORIAL OFFICES 5635 Fishers Lane, Suite 6000, Rockville, MD 20852, 240-221-4500, fax 240-221-2541




Pulmonary Artery Pressure Rise Linked to Mortality

BY MITCHEL L. ZOLER
Elsevier Global Medical News

NEW ORLEANS — Pulmonary artery systolic pressure may increase with age among unselected, otherwise healthy people in the general population, based on a cross-sectional study of more than 1,400 people.

In addition, the age-associated rise in pulmonary artery systolic pressure (PASP), which was strikingly parallel

PASP Increased With Age (in mm Hg)



Source: Dr. Lam

with the age-related rise in systolic blood pressure, was also independently associated with an increased risk for death.

For every 10-mm Hg rise in PASP among unselected, otherwise healthy people in the general population, the risk of death rose 2.7-fold in an analysis that adjusted for age, Dr. Carolyn S. Lam reported at the annual Scientific Sessions of the American Heart Association.

"This is the first population-based evidence for an age-related rise in PASP," said Dr. Lam, a cardiologist at the Mayo Clinic in Rochester, Minn.

Results from prior studies had found a similar age-related rise in PASP, but it was in patients who had been sick enough to be referred for assessment by right heart catheterization or by echocardiography.

"What was interesting was it was so analogous to the rise in systolic blood pressure," she noted. Dr. Lam and her associates speculated that the age-related rise in PASP may be related to increased arterial stiffness with age, the process that is believed to also underlie increased systolic blood pressure with age.

The study included 1,413 residents of Olmsted County, Minn., age 45 years or older, who were seen at the Mayo Clinic for routine physical examinations. None of those people was initially diagnosed with cardiovascular disease.

As part of their examination, however, they underwent an echocardiography study that measured their tricuspid regurgitation velocity. That value was used to calculate their PASP. Their average age was 63 years, 57% were men, and their average body mass index was about 28 kg/m².



'This is the first population-based evidence for an age-related rise' in pulmonary artery systolic pressure.

DR. LAM

The median PASP in the group was 26 mm Hg, with an intraquartile range of 24-30 mm Hg. Dr. Lam divided the subjects into quartiles by age, and found that their PASP steadily rose with age, from an average of 26 mm Hg among those aged 45-54 years to an average of 30 mm Hg among those aged 72 years or older (see graphic). Those age quartiles also showed the expected, age-related rise in systolic blood pressure.

Although the increments in systolic pressure with age were greater than the rise in PASP, that was because systolic blood pressures generally are higher.

When the age-related rise in PASP was adjusted by the baseline level in the youngest quartile, the age-related rise was "strikingly similar" to the age-related rise for systolic blood pressure, Dr. Lam said.

In addition, the age-related rise in PASP was independent of the age-related rise in pulse pressure and in diastolic dysfunction.

To assess the impact of a rise in PASP on survival, Dr. Lam limited her analysis to the 778 people from the study group who were completely free of any cardiopulmonary disease based on their physical examination. Some of those "healthy" people had PASP levels that were as high as 66 mm Hg.

Analysis showed that the risk of death increased with increased PASP regardless of age, suggesting that PASP may be a "lifelong risk factor," Dr. Lam said.

The findings suggest that drug interventions aimed at reducing PASP, with agents such as calcium-channel blockers or phosphodiesterase-5 inhibitors such as sildenafil, may help reduce PASP-related deaths.

Before a study is done to test the efficacy of treatments aimed at lowering PASP, however, the prognostic role of elevated PASP must be explored in additional studies in different populations, Dr. Lam cautioned. ■

Respiratory Illnesses Tied to Later Asthma

BY SUSAN LONDON
Elsevier Global Medical News

SEATTLE — Children prone to atopy are more likely to develop asthma if they frequently have moderate to severe respiratory illnesses in the first years of life, according to results of a prospective cohort study. Moreover, these illnesses do not protect against other atopic conditions.

Childhood respiratory illnesses cause considerable morbidity, contribute to parental absence from work, and are one of the most common causes of health care visits among the pediatric population, lead author Dr. Christine Virnig noted at the annual meeting of the American College of Allergy, Asthma, and Immunology.

"We sought to further understand the risk factors for and atopic consequences of having frequent respiratory illnesses during the first 3 years of life," she said.

The investigators analyzed data from 277 children in the Childhood Origins of Asthma (COAST) study, which enrolled a birth cohort of infants who were at high risk for atopic conditions because at least one parent had allergies, asthma, or both.

During the children's first 3 years of life, parents completed a scorecard whenever their child had a respiratory illness to document the frequency and severity of these illnesses, said Dr. Virnig, an allergy and immunology

fellow at the University of Wisconsin, Madison.

The children's personal, family, and environmental characteristics were assessed between birth and 6 years. Total IgE levels, eosinophil counts, levels of antigen-specific IgE to food and airborne allergens, and presence of atopic dermatitis were assessed at 1, 3, and 6 years, and the presence of asthma was assessed at 6 years.

Scorecard results indicated that 8% of the children did not have any moderate to severe respiratory illnesses (MSIs) during the first 3 years of life, whereas 9% had frequent MSIs (12 or more), Dr. Virnig reported.

Not unexpectedly, she said, children who had frequent MSIs were significantly more likely to have attended day care in their first 6 months of life, compared with their counterparts who did not have any MSIs during those years (64% vs. 27%).

But in a surprising finding, children with frequent MSIs also were significantly more likely to have been exclusively breastfed for the first 6 months of life (52% vs. 18%).

This association remained significant when the number of MSIs was analyzed as a continuous variable, but the ranges of values overlapped considerably. "Therefore, the clinical significance of this finding is very uncertain," Dr. Virnig commented, adding that it would not justify altering recommendations to breastfeed.

Children with frequent MSIs also were marginally more likely to have a mother who had asthma. A variety of other factors—sex, birth weight, presence of an older sibling, smoke exposure, a cat or dog in the home at birth, and paternal asthma—did not differ between groups.

The prevalence of asthma at age 6 was significantly higher among children having frequent MSIs than in children having none of them (59% vs. 9%). This association also remained significant when the number of illnesses was analyzed as a continuous variable, although the ranges of values again overlapped.

There was no significant difference between the two groups in terms of atopic dermatitis, the presence of food-specific IgE, or the presence of aeroallergen-specific IgE—or eosinophil counts at any of the ages studied.

Dr. Virnig acknowledged that the findings appear to be at odds with the hygiene hypothesis, which proposes that early infectious illnesses protect against subsequent allergies.

However, she noted, evidence supporting this hypothesis has generally been strongest for gastrointestinal illnesses, while several studies have in fact found an opposite pattern for respiratory illnesses, particularly those of the lower respiratory tract.

Dr. Virnig reported that she had no conflicts of interest in association with the study. ■

First Editor in Chief Ends Her Term



The ACCP gratefully recognizes Dr. Susan M. Harding, FCCP, (right) and Arren Graf (left).

In January 2006, the first edition of CHEST PHYSICIAN was ushered in by its first editor in chief, Dr. Susan M. Harding, FCCP, and so began the road to success of the new ACCP newspaper aimed at providing relevant clinical information and the latest news in chest medicine, plus ACCP updates, to members and others.

During the past 3 years, Dr. Harding has built a publication that offers timely, relevant updates for ACCP members and others. Her excellent editorial skills, attention to detail, and broad chest medicine knowledge have been evident in every issue, and the popularity and value of CHEST PHYSICIAN to our members are much to her credit. The ACCP gratefully recognizes Dr. Harding and her indispensable editorial assistant, Arren Graf, for their selfless provision of time and effort in making CHEST PHYSICIAN the upstanding, professional chest medicine news vehicle it is today.

Thank you, Dr. Harding and Arren! ■

Hospitals Test Blood Programs

Blood Costs • from page 1

these, she said in an interview. “Even though patients don’t have a major reaction to a transfusion, it does depress the immune system. And when you are dealing with people who are already sick enough to need a transfusion, this puts them at an even higher risk of infection, longer length of stay, and a host of other complications.”

The risk of blood-borne infections, while minimized with donor screening methods, can never be completely eliminated, she added. “We have the safest blood supply in the world, but we can never make it 100% safe.”

And the very storage techniques that extend blood’s shelf life also contribute to its demise, she added. “We keep blood for up to 42 days, but even after 14 days in storage, you can see changes,” Ms. Tolich said, including lesions on the red cells that can cause capillary occlusion.

A Cleveland Clinic study pointed out the risks of using stored blood in a group of cardiac patients.

Compared with those who received blood stored a median of 11 days, patients who received blood stored a median of 20 days were more likely to die in the hospital, and have longer periods of intubation, more renal failure, and more sepsis. Even at 1 year, patients

who got the older blood were more likely to have died (N. Engl. J. Med. 2008;358:1229-39).

Economics cap off the clinical issues. According to the National Blood Data Resource Center, the 15 million or so annual allogeneic blood transfusions in the United States cost more than \$2 billion—not including the costs of any transfusion-related complications.

A 2007 report by the American Association of Blood Banks concluded costs to use blood rose by more than 6% per unit from 2005 to 2006.

Using Blood Better

The Cleveland Clinic program is one of the country’s most mature. It was the first to gain accreditation by the only group that offers such an endorsement, the American Association of Blood Banks.

Because there are no national requirements, hospitals are developing their own programs individually and at their own pace, Dr. Kumar said. “Everyone is in a different stage of development, and no one has the perfect system.”

At his facility, however, physician accountability is the primary focus. Scorecards detailing transfusion practices are becoming part of every physician’s annual review.

“Every blood order has to indicate the reason. We expect physicians to examine patients at the bedside before ordering blood, and document the reason for the decision,” Dr. Kumar said. “We’re also making staff physicians responsible for what their residents are doing—it’s been a really radical change.”

There’s no one-size-fits-all algorithm deciding who gets blood and who doesn’t, Dr. Kumar said. “We judge each patient on their clinical characteristics before giving blood.”

“If an 82-year-old lady with hemoglobin of 9 g/dL after surgery feels terrible and gets out of breath, a transfusion is probably a good idea,” he explained. “But a healthy 32-year-old man with the same hemoglobin after surgery might feel fine, because his body is able to compensate. The trigger changes with the patient.”

Preoperative conditioning is an important part of the program, Ms. Tolich said. In the weeks before a scheduled surgery, patients with low hemoglobin visit outpatient anemia clinics. Red cell growth factor and intravenous iron are good options for building up hemoglobin.

Normovolemic hemodilution can be employed shortly before surgery. “In the holding area, we withdraw blood and replace it with an equal part of intravenous solution,” Ms. Tolich explained. “When they lose blood during surgery, they’re losing fewer red blood cells. Then the stored blood can be re-administered.”

Self-banking isn’t really a good option, Ms. Tolich added. “This is not supported by the medical evidence. It makes patients anemic going into surgery, so they’re not only more likely to need that blood, but additional donor blood,” she said. “And if all of the predonated blood isn’t used, it has to be disposed of as medical waste. Predonation is also actually more expensive than using donor blood.”

It’s no surprise that the Cleveland Clinic program resembles that of the University of Pittsburgh Medical Center—Dr. Jonathan Waters, medical director of the University of Pittsburgh Health System’s perioperative blood management program founded the Ohio program.

In addition to preoperative conditioning, the Pittsburgh program employs intraoperative blood cell salvage. Shed blood is collected, filtered, washed, and re-administered during surgery. The hospitals in Dr. Waters’ institution perform about 8,000 salvage procedures yearly.

The Pittsburgh program also relies heavily on point-of-care testing.

“These devices measure blood parameters with a very small volume of blood, and the turnaround is 30 seconds. This allows you to strategize how to transfuse the patient,” Dr. Waters said.

With the old 1-hour turnaround time for these tests, “if someone was bleeding, you just gave them everything you had,” he said. “Since we’ve turned to point-of-care testing, we’ve had a 70% decrease in blood use.”

That kind of reduction soon pays for any investment in transfusion-minimizing equipment, Dr. Waters pointed out.

A 2007 study concluded that the

intraoperative blood cell salvage service at the Cleveland Clinic, which initially cost \$103,500, paid for itself with 2 months’ worth of reduced blood costs (Anesth. Analg. 2007;104:869-75).

Voluntary—for Now

Hospital blood management programs are a growing phenomenon, but by no means a universal one. Accreditation is based on voluntary compliance with standards set forth by the American Association of Blood Banks, but that may change in the future, Dr. Waters said.

“Two years ago, the Joint Commission formed a committee with representatives from interested parties on the provider side to determine if the commission should develop evidence-based blood management performance measures, which everyone thought was a good idea,” Dr. Waters noted.

The committee came up with 19 possible measures, ranging from administrative to clinical, and posted them on the Internet for public comment. That comment period is over now, and the committee is about to winnow the measures down to a more practical number.

Funding could throw a wrench in the process, though, said Linda Hanold, the Joint Commission’s director of quality measurement. Bayer Healthcare Pharmaceuticals funded the initial phase of the project with an unrestricted educational grant. But the money has run out, and Ms. Hanold isn’t sure where the next grant might come from.

“Developing these measures usually takes about 27 months and costs around \$600,000,” she said.

If funding is secured, the measures will go through a testing process before publication in 2010. If not, the Joint Commission will publish the prospective performance measures and supporting evidence as a monograph, probably sometime in 2009. Either way, the measures will reside in the Joint Commission’s Measure Reserve Library, ready for implementation if a national mandate is handed down.

Until then, organizations can still make free use of the performance measures, Ms. Hanold said. “They can be used at the organizational level, adapted by individual organizations, or promoted for use by professional societies.”

But implementation of any performance measures will remain primarily local until and unless legislative action makes measurement of blood management a nationally supported priority.

“These measures won’t be used for accreditation until they are endorsed at the national level,” Ms. Hanold said. “I can’t predict when that will be, but it is an issue receiving growing attention.” ■

Dr. Philip Marcus, MPH, comments:

Things we have taken for granted now deserve a second look. We previously used transfusions without thinking twice: A low hematocrit meant a transfusion was going to be ordered. We have learned a lot since those days, and now—with a looming blood shortage and the economics of blood donation, storage, and transfusion—we have re-evaluated how we use this precious commodity. Old blood has already been shown to result in poorer outcomes for those receiving it.

**CELEBRATION
OF PEDIATRIC
PULMONOLOGY
2009**

April 3-5
Hilton Scottsdale Resort & Villas
Scottsdale, Arizona

Course Chairs
LeRoy Graham, MD, FCCP
Dennis Gurwitz, MBBCh, FAAP
Pedro Mayol, MD, FCCP

Review the latest findings in clinical pediatric pulmonology during this state-of-the-art update. The course will combine plenary-style lectures, question and answer sessions, interactive small group workshops, and case presentations, so you benefit from a wide variety of learning methods.

Register Early and Save.
Visit our Web site for details, or contact ACCP Customer Relations.
www.chestnet.org
(800) 343-2227 or +1 (847) 498-1400

American Academy of Pediatrics
DEDICATED TO THE HEALTH OF ALL CHILDREN

AMERICAN COLLEGE OF
CHEST
PHYSICIANS®

Panels Debate LABAs for Asthma

Monotherapy • from page 1

should remain on the market and, if so, how their risks should be managed.

GlaxoSmithKline markets Serevent and Advair, Novartis markets Foradil, and AstraZeneca Pharmaceuticals markets Symbicort. The companies presented their own data analyses at the meeting.

Support for the use of Advair in children aged 4-11 years was mixed: The panels voted 13-11, with 3 abstentions, that Advair's benefits outweighed its risks for the maintenance treatment of asthma. Advair, marketed by Glaxo-SmithKline, is approved for children ages 4 years and older. Symbicort is approved for children as young as age 12 years, so the panels did not vote on the younger age group for that product.

The panelists' primary concern was that a LABA not be used as monotherapy for maintenance treatment in patients with asthma. They also recommended that when a LABA is used, it always be combined with an ICS, reflecting current asthma treatment guidelines.

Some panelists noted that the labeling for the single-ingredient products was not strong enough regarding the importance of combining them with an ICS for asthma. The panelists also agreed that more safety data were needed for children using Advair and Symbicort.

LABAs "are too dangerous to use without an ICS for asthma in any age group," said Sean Hennessy, Pharm.D., of the University of Pennsylvania, Philadelphia, and a member of the drug safety committee.

The FDA and the manufacturers agreed that a LABA should never be used without an ICS for treating asthma, although evidence that ICS use with a LABA "nullifies LABA-related risks is lacking," Dr. Andrew Mosholder, a medical officer in the FDA's Office of Surveillance and Epidemiology (OSE), said at the meeting. There was no disagreement that the risk associated with LABAs is real. However, ICS use in studies was usually only documented at baseline, not throughout the studies, Dr. Mosholder noted.

Within the FDA, however, there were mixed opinions about how to deal with the risk. The OSE recommended that the asthma indication for all LABAs be withdrawn for people younger than 18 years, and that the asthma indication for single-ingredient LABAs be removed for all age groups. The Division of Pulmonary and Allergy Drug Products, however, recommended that the LABAs remain on the market for asthma, with stronger labeling that addressed their safety risks.

"There's no doubt" that LABAs have improved the lives of children with asthma, and it would be "irresponsible" to withdraw them from the market, said panelist Dr. Fernando Martinez, director of the Arizona Respiratory Center at the University of Arizona, Tucson. He said he has not prescribed monotherapy with a LABA alone for at least 5 years.

"I don't consider the benefits trivial at all," said Dr. Jesse Joad, another pediatric pulmonologist on the panel, who described the advent of the drugs as a

"revolution" in treating pediatric asthma. However, the single-ingredient products should not be used for asthma, said Dr. Joad, professor and vice chair of pediatrics at the University of California, Davis. The availability of Advair in three ICS strengths provides dosing flexibility, she noted.

The meeting was held nearly 6 years after the Salmeterol Multicenter Asthma Research Trial (SMART), a large, randomized, double-blind study comparing salmeterol inhalation aerosol with placebo in about 26,000 people with asthma who were at least age 12 years (about 12% were 12-18 years old). SMART stopped early, in January 2003, because of recruitment problems.

The study results showed a small but significant increase in asthma-related deaths after 28 weeks among patients using salmeterol, compared with patients on placebo (13 deaths vs. 3 deaths, a relative risk of 4.4); the risk appeared to be higher among black patients. A paradoxical finding was that although some severe events increased with treatment, immediate symptoms improved with treatment.

At the December meeting, the FDA presented a new meta-analysis of previously available data obtained from the manufacturers. The data were drawn from 110 trials of Advair, Serevent, Foradil, and Symbicort in about 61,000 people aged 4-100 years (median age 37 years). The median treatment time was about 6 months. About half of patients reported using an ICS at baseline.

LABA treatment was associated with an increased risk of asthma-related events, compared with treatment that did not include a LABA (such as an ICS, short-acting β -agonist, or other

non-LABA treatment), as measured by a composite end point of asthma-related deaths, asthma-related intubations, and asthma-related hospitalizations. There were 20 asthma-related deaths: 16 in the LABA group (all in Serevent-treated patients) and 4 in the non-LABA group.

The increased risk associated with LABAs, as measured by the composite end point, was not seen with Advair, according to the FDA. Children ages 4-11 years appeared to be at the greatest risk, compared with other age groups. In addition, black patients were at a greater risk than other races, and women were at a greater risk than men.

The three FDA advisory committees' exact vote tallies were as follows: For Advair, the panels voted 27-0 in favor of the benefit-risk profile for adults 18 years and older, and 23-3 with 1 abstention for adolescents 12-17 years. For Symbicort, for which there are far fewer data than for Advair, the panel voted 26-0 with 1 abstention in favor of the benefit-risk profile in adults 18 years and older, and 20-5 with 2 abstentions for adolescents 12-17 years.

By a vote of 17-10, the panelists agreed that the benefits of Serevent did not outweigh its risks for maintenance treatment of asthma in adults. They reached the same conclusion regarding its use in adolescents (21-6 vote) and in children ages 4-11 years (unanimous vote).

For Foradil, the panels agreed that the benefits did not outweigh its risks in adults by a vote of 18-9, and in adolescents by a vote of 21-6. The panels also unanimously agreed that the benefits of Foradil did not outweigh its risks in younger children. ■

FDA Committees' Ruling on Safety of LABAs: What It Means for Clinicians

BY DR. JAY PETERS, FCCP
Chair, ACCP Airways Disorders NetWork

The Dec. 11, 2008, joint ruling by three of the U.S. Food and Drug Administration's advisory committees should make clinicians stop and consider the risks and benefits of long-acting β -agonist use in patients with asthma.

Fortunately, the joint panel voted unanimously that both salmeterol and formoterol (which are approved for maintenance therapy and prevention of bronchospasms in adults, adolescents, and children) should not be taken off the market. Combined with inhaled corticosteroids (ICS), they have dramatically improved the quality of life for our patients, compared with the era in which theophylline was second-line therapy for moderately severe asthma.

The concern stems from the fact that these agents (LABAs) have clearly been shown to increase the risk of severe asthma exacerbations when taken as monotherapy.¹ The FDA's Office of Surveillance and Epidemiology recommended that the indication for LABAs be withdrawn for asthmatics younger than 18 years of age, based on the potential risks and the limited comparative data in children and young adults.

Answers to the questions related to the comparative effect of increasing ICS to medium dose or adding a LABA or leukotriene blocker to low dose ICS await the completion of the National Institutes of Health's Childhood Asthma Research and Education (CARE) Network study that should be presented in early 2010.

In adult patients, there is little doubt that the combined use of ICS and LABAs has resulted in significant improvement in the quality of life and an overall reduction in asthma exacerbations. The question remains as to what the risks of LABAs are, and whether they are completely ameliorated by the combined use of ICS.

The main concern regarding the risk of LABAs comes from the 2006 SMART study, in which there were 3 deaths out of 13,000 patients in the placebo group and 13 deaths out of 13,000 patients in the active treatment arm.² This study also raised concerns that the increased risk of mortality was higher in African Americans. However, only half of patients in the SMART study were using ICS, and documentation of ICS use was not obtained throughout the trial.

The recent FDA analysis of 110 trials of Advair, Serevent, Foradil, and Symbicort should be both a comfort and a warning to physicians. It supports the concept that the combination of ICS/LABA has a very favorable benefit/risk ratio. In this analysis, ICS/LABA (Advair) demonstrated no increased risk of the combined end points (asthma-related deaths, intubations, or hospitalizations), and, importantly, all the LABA deaths were in patients treated with LABA alone.

It should also serve as a warning that when LABAs and ICS are written as separate prescriptions (which often occurs for reasons of cost/insurance plans), poorly compliant patients who fill only one medication and rely on their long-acting bronchodilator place themselves at increased risk for severe exacerbation or death.

Overall, I think clinicians should rely on the

National Asthma Education and Prevention Program's Expert Panel guidelines that considered these issues in depth when they wrote the 2007 EPR-3: Guidelines for the Diagnosis and Management of Asthma.³ The combination of ICS/LABA should not be used in patients with mild asthma, and step-down therapy should be considered in every asthmatic patient who has been stable for 3-6 months. Physicians should reserve the use of ICS/LABA as preferred therapy for persistent asthma only when indicated (step 3 therapy in children 5-11 years of age, and in children 12 years of age or older/adults; step 4 therapy in children 0-4 years of age).

There is no doubt that LABAs should not be used as monotherapy for asthma management in either children or adults and that physicians should assess the benefits and risks in patients at high risk for severe exacerbation and in poorly compliant patients.

References

- Lemanske J, Sorkness C, Mauger E, et al, and the Asthma Clinical Research Network. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. *JAMA* 2001;285:2594-2603
- Nelson H.S., Weiss S.T., Bleecker E.R., et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* 2006;129:15-26
- National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. *J. Allergy Clin. Immunol.* 2007;120(suppl):S94-S138

PRACTICE MANAGEMENT

New Medicare Fee Schedule Payments Compared With 2008

The Centers for Medicare & Medicaid Services (CMS) reported the 2009 Medicare conversion factor of \$36.0666 as a 1.1% increase over 2008. This conversion factor is actually \$2.02 lower than the 2008 Medicare conversion factor of \$38.09.

However, Dr. Scott Manaker, FCCP, the ACCP advisor to the AMA Relative Value Scale (RVS) Update Committee (RUC) says, "While the conversion factor is lower, there is actually an increase in overall payment for physician services."

The overall impact for this year for pulmonary medicine is reported by CMS as a positive 3%. Last year, there was a reduction in physician work relative values as a result of budget neutrality, which was meant to offset increases to the evaluation and management codes, including critical care services, determined through the RUC's third Five-Year Review.

Organized medicine questioned CMS about this and, in 2009, it has been corrected. "This results in a lowering of the conversion factor but an increase in value for most of the work we do, resulting in higher payments for evaluation and management services; however, there is a lower value for technical

and procedural services," said Dr. Michael Nelson, FCCP, Chair, ACCP's Practice Management Committee.

The accompanying table of selective pulmonary services and procedures provides some examples of the

changes and represents nationalized payment rates. A physician's individual rate is affected by a geographic practice cost index factor based on where your practice is located.

The final rule can be reviewed at

www.access.gpo.gov/su_docs/fedreg/a081119c.html. Visit the expanded and continually updated ACCP Practice Management Web page at www.chestnet.org/practice/pm/index.php.

Medicare Physician Fee Schedule Nationalized Payments

(Subject to Geographic Adjustments)

CPT	Descriptor	2009 Nonfacility (office)	2008 Nonfacility (office)	Percent change	2009 Facility (hospital, OPD)	2008 Facility (hospital, OPD)	Percent change
31620	EBUS	\$263.29	\$273.08	-3.7%	\$68.89	\$67.79	+1.6%
31622	Dx bronch/wash	296.11	307.74	-3.9%	141.38	137.49	+2.8%
31623	Dx bronch/brush	323.52	337.83	-4.4%	142.46	138.64	+2.7%
31624	Dx bronch/lavage	300.80	313.46	-4.2%	142.82	138.64	+3.0%
31625	Bronch w/biopsies	324.60	334.78	-3.1%	166.63	161.87	+3.0%
94010	Breathing capacity test	32.82	33.90	-3.3%	NA	NA	
-26	Professional component	8.30	8.00	+3.7%	8.30	8.00	+3.7%
-TC	Technical component	24.53	25.90	-5.6%	NA	NA	
94060	Evaluation of wheezing	57.71	58.27	-1.0%	NA	NA	
-26	Professional component	14.43	13.71	+5.0%	14.43	13.71	+5.0%
-TC	Technical component	43.28	44.56	-2.9%	NA	NA	
95012	Exhaled NO	19.48	19.04	+2.3%	NA	NA	
95811	Polysomnography/CPAP	845.40	891.24	-5.4%	NA	NA	
-26	Professional component	181.78	176.34	+3.0%	181.78	176.34	+3.0%
-TC	Technical component	663.63	714.89	-7.7%	NA	NA	
99213	Office/outpatient established	61.31	59.80	+2.5%	44.72	41.90	+6.4%
99214	Office/outpatient established	92.33	89.89	+2.7%	69.25	65.51	+5.5%
99215	Office/outpatient established	124.79	121.50	+2.7%	98.46	94.07	+4.5%
99233	Subsequent hospital care	NA	NA		95.58	90.65	+5.2%
99244	Office consultation	184.30	179.01	+2.9%	154.00	145.49	+5.5%
99254	Inpatient consultation	NA	NA		165.55	156.54	+5.5%
99291	Critical care, 1st hour	253.91	250.99	+1.2%	212.07	204.15	+3.8%
99292	Critical care, additional 30 min	114.69	111.98	+2.4%	106.04	102.45	+3.4%

ELSEVIER GLOBAL MEDICAL NEWS

CALL FOR ABSTRACTS

CHEST
2009 October 31 - November 5
San Diego, California

Submit Abstracts for CHEST 2009

Be part of CHEST 2009 by submitting an abstract of your original investigative work for presentation before thousands of physicians. Authors of accepted abstracts will be eligible for The CHEST Foundation investigative awards.

**ABSTRACT
SUBMISSIONS
OPEN**

January 12 - May 4, 2009

Watch www.chestnet.org
for details.

CELEBRATING **75** YEARS OF INSPIRATION |
1935 - 2009

Meet New Ambassadors Group Chair

Born and raised in Richmond, Virginia, Susan Mathers is delighted to serve as the Ambassadors Group Chair for 2008-2009. Susan is the wife of Dr. James A. L. Mathers, Jr., FCCP, the ACCP President for 2008-2009.

She has two older brothers, a younger sister, and a father who is doing great at 85. She quit work to help her dad take care of her mother who had Alzheimer disease for 14 years and says it taught her a lot about life and what is really important. Susan



MS. MATHERS


has one son, Matthew, 28, who recently got engaged.

Susan went to Stratford College in Danville, VA, and majored in art history (and having fun!). She loves to walk outside 4 miles a day (weather permitting) and, in addition, enjoys decorating, hunting for unusual bargains, and kayaking. Her greatest joy is doing things for and with her husband, Jim, their families, and friends.

As Ambassadors Group Chair, she would like to continue the presentations at the CHEST meetings from international members of the Ambassadors Group. The presentations on India at CHEST 2008 by Anita and Pratima Mathur and Sabiha Raoof were excellent and enjoyed by all. She noted that being an Ambassadors Group member has afforded her the opportunity to make many new friends from all over the United States and the world. She would like to present the Lung LessonsSM program, developed by The CHEST Foundation, in schools, similar to what Susan Kvale does when accompanying her husband on ACCP trips. She invites other members to help present these lessons, as well.

As Chair, she welcomes new ideas or worthwhile projects that will help further the work of The CHEST Foundation. One area she would like to focus on is the damage secondhand smoke causes to children and, in particular, those with asthma. "We need to educate parents and other family members who smoke that secondhand smoke affects the lungs of their children and exacerbates asthma," she said. "The result is not only frequent physician and emergency room visits but possible long-term lung damage."

STERILE TALC POWDER™



Visit us at STS Booth #921

Exclusive Features:

FDA APPROVED

- Gamma Irradiated • Single Use, 5 gram Dosage • Controlled Particle Size
- Packaged Sterile in a 100ml Glass Vial • Chest tube administration

Sclerosol[®] Intrapleural Aerosol is indicated or use as a sclerosing agent to decrease the recurrence of Malignant Pleural Effusion (MPE) in symptomatic patients. A cost-effective treatment, Sterile Talc Powder provides uniform, consistent and clean administration.

DESCRIPTION

Sterile Talc Powder is a sclerosing agent intended for intrapleural administration supplied in a single use 100 ml brown glass bottle, sealed with a gray, 20 mm stopper and covered with a flip-off seal. Each bottle contains a minimum of 5.0 g of Talc USP (Ultra 2000 Talc), either white or off-white to light gray, asbestos-free and brucite-free grade of talc of controlled particle size. The composition of the talc is 95% talc as hydrated magnesium silicate. The empirical formula of talc is Mg₃Si₄O₁₀(OH)₂ with a molecular weight of 379.3. Associated naturally occurring minerals include chlorite (hydrated aluminum and magnesium silicate), dolomite (calcium and magnesium carbonate), calcite (calcium carbonate) and quartz. Talc is practically insoluble in water and in dilute solutions of acids and alkali hydroxides. The finished product has been sterilized by gamma irradiation.

CLINICAL PHARMACOLOGY

Mechanism of Action

The therapeutic action of talc instilled into the pleural cavity is believed to result from induction of an inflammatory reaction. This reaction promotes adherence of the visceral and parietal pleura, obliterating the pleural space and preventing reaccumulation of pleural fluid.

The extent of systemic absorption of talc after intrapleural administration has not been adequately studied. Systemic exposure could be affected by the integrity of the pleural surface, and therefore could be increased if talc is administered immediately following lung resection or biopsy.

INDICATIONS AND USAGE

Sterile Talc Powder, administered intrapleurally via chest tube, is indicated as a sclerosing agent to decrease the recurrence of malignant pleural effusions in symptomatic patients.

CONTRAINDICATIONS

None known

WARNINGS

None

PRECAUTIONS

1. Future procedures: The possibility of the future diagnostic and therapeutic procedures involving the hemithorax to be treated must be considered prior to administering Sterile Talc Powder. Sclerosis of the pleural space may preclude subsequent diagnostic procedures of the pleura on the treated side. Talc sclerosis may complicate or preclude future ipsilateral lung resective surgery, including pneumonectomy for transplantation purposes.

2. Use in potentially curable disease: Talc has no known antineoplastic activity and should not be used alone for potentially curable malignancies where systemic therapy would be more appropriate, e.g., a malignant effusion secondary to a potentially curable lymphoma.

3. Pulmonary complications: Acute Pneumonitis and Acute Respiratory Distress Syndrome (ARDS) have been reported in association with intrapleural talc administration. Three of the case reports of ARDS have occurred after treatment with a relatively large talc dose (10 g) administered via intrapleural chest tube instillation. One patient died one month post treatment and two patients recovered without further sequelae.

DRUG INTERACTIONS

It is not known whether the effectiveness of a second sclerosing agent after prior talc pleurodesis would be diminished by the absorptive properties of talc.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies on the carcinogenicity of talc have been performed using non-standard designs which prevent firm conclusions on its carcinogenicity. With single intraperitoneal administration to mice at 20 mg and observation for at least 6 months or 4 weekly doses administered intraperitoneally at 25 mg/dose to rats with observation for at least 84 weeks, tumor incidence was not increased. In these studies the talc and its asbestos content were not characterized.

Genotoxicity was tested in cultures of rat pleural mesothelial cells (RPMC) as unscheduled DNA synthesis (UDS) and sister chromatid exchanges (SCEs). None of the talc samples (which were asbestos-free) induced enhancement of UDS or SCEs in treated cultures. No information is available on impairment of fertility in animals by talc.

Pregnancy: Pregnancy Category B. An oral administration study has been performed in the rabbit at 900 mg/kg. Approximately 5 fold higher than a human dose on mg/m² basis, and has revealed no evidence of teratogenicity due to talc. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should not be used during pregnancy unless the benefit outweighs the risk.

Pediatric Use: The safety and efficacy of Sterile Talc Powder in pediatric patients have not been established.

Geriatric use: The estimated mean and median ages of patients treated with talc slurry from clinical studies (single-arm or randomized) were 60 and 62 years, respectively. No analyses to specifically evaluate the safety and efficacy in the geriatric population have been reported.

ADVERSE REACTIONS

Intrathoracic administration of talc slurry has been described in medical literature reports involving more than 2000 patients. Patients with malignant pleural effusions were treated with talc via poufrage or slurry. In general, with respect to reported adverse experiences, it is difficult to distinguish the effects of talc from the effects of the procedure(s) associated with its administration. The most often reported adverse experiences to intrapleurally-administered talc were fever and pain.

Infection: Complications reported include empyema.

Respiratory: Complications reported include hypoxemia, dyspnea, unilateral pulmonary edema, pneumonia, ARDS, bronchopleural fistula, hemoptysis and pulmonary emboli.

Cardiovascular: Complications reported included tachycardia, myocardial infarction, hypotension, hypovolemia and asystolic arrest.

Delivery Procedure: Adverse reactions due to the delivery procedure and the chest tube may include: pain, infection at the site of thoracostomy or thoracoscopy, localized bleeding, and subcutaneous emphysema.

Chronic Toxicity: Since patients in clinical studies had a limited life expectancy, data on chronic toxicity are limited.

OVERDOSAGE

No definite relationship between dose and toxicity has been established. Excessive talc may be partially removed with saline lavage.

DOSAGE AND ADMINISTRATION

Sterile Talc Powder should be administered after adequate drainage of the effusion. The success of the pleurodesis appears to be related to the completeness of the drainage of the pleural fluid, as well as the full re-expansion of the lung, both of which will promote symphysis of the pleural surfaces.

The recommended dose is 5 g, dispersed in 50 - 100 ml Sodium Chloride Injection, USP. Although the optimal dose for effective pleurodesis is unknown, 5 g was the dose most frequently reported in the published literature.

Talc Preparation

Prepare the talc slurry using aseptic technique in an appropriate laminar flow hood. Remove talc container from packaging. Remove protective flip-off seal.

Each brown bottle contains 5 g of Sterilized Talc Powder. To dispense the contents:

1. Using a 16 gauge needle attached to a 60-ml LuerLok syringe, measure and draw up 50 ml of Sodium Chloride Injection, USP. Vent the talc bottle using a needle. Slowly inject the 50 ml of Sodium Chloride Injection, USP into the bottle. For doses more than 5 g, repeat this procedure with a second bottle.
2. Swirl the bottle(s) to disperse the talc powder and continue swirling to avoid settling of the talc in the slurry. Each bottle will contain 5 g Sterile Talc Powder dispersed in 50 ml of Sodium Chloride Injection, USP.
3. Divide the content of each bottle into two 60 ml irrigation syringes by withdrawing 25 ml of the slurry into each syringe with continuous swirling. QS each syringe with Sodium Chloride Injection, USP to a total volume of 50 ml in each syringe. Draw air into each syringe to the 60 ml mark to serve as a headspace for mixing prior to administration.
4. When appropriately labeled, each syringe contains 2.5 g of Sterile Talc in 50 ml of Sodium Chloride Injection, USP with an air headspace of 10 ml. Once the slurry has been made, use within 12 hours or discard and prepare fresh slurry. Label the syringes appropriately noting the expiration date and time, with the statement "For Pleurodesis Only - NOT FOR IV ADMINISTRATION," the identity of the patient intended to receive this material and a cautionary statement to SHAKE WELL before use.
5. Prior to administration, completely and continuously agitate the syringes to evenly redisperse the talc and avoid settlement. Immediately prior to administration, vent the 10 ml air headspace from each syringe.
6. Attach the adapter and place a syringe tip on the adapter. Maintain continuous agitation of the syringes.

NOTICE: Shake well before installation. Each 25 ml of prepared slurry in the syringe contains 1.25 g of talc. NOT FOR IV ADMINISTRATION.

Administration

Administer the talc slurry through the chest tube by gently applying pressure to syringe plunger and empty the contents of the syringe into the chest cavity. After application, discard the empty syringe according to general hospital procedures. After the talc slurry has been administered through the chest tube into the pleural cavity, the chest tube may be flushed with 10- 25 ml sodium chloride solution to ensure that the complete dose of talc is delivered.

Following introduction of the talc slurry, the chest drainage tube is clamped, and the patient is asked to move, at 20 to 30 minute intervals, from supine to alternating decubitus positions, so that over a period of about 2 hours the talc is distributed within the chest cavity. Recent evidence suggests that this step may not be necessary.

At the end of this period, the chest drainage tube is unclamped, and the excess saline is removed by the routine continual external suction on the tube.

HOW SUPPLIED

NDC 63256-200-05 Sterile Talc Powder is supplied in a 100 ml brown glass bottle containing 5 g of talc. The sterile bottle is closed with a gray stopper and covered with a flip-off seal.

Storage: Store at Room Temperature (18-25°C). Protect against sunlight.

DISTRIBUTED BY: Bryan Corporation, Woburn, MA 01801



To place an order or for more information on Product #1680, Sclerosol[®] Intrapleural Aerosol, please contact Bryan Corporation at: **800-343-7711 or visit us at www.bryancorp.com**



SLEEP STRATEGIES

Home Sleep Apnea Testing Final Regulations Debut

The Grateful Dead once sang the song "Truckin" with the famous lyrics, "what a long, strange trip it's been." Physicians who practice sleep medicine have certainly observed a long, strange trip over recent years. Indeed, few would disagree that it has been a long, strange road to the present state of affairs, whereby the Centers for Medicare and Medicaid Services (CMS) approved reimbursement for home sleep apnea testing (HSAT), also referred to as portable monitoring (PM), for the diagnosis of obstructive sleep apnea (OSA) and continuous positive airway pressure (CPAP) treatment.

In the early 1990s, there was limited scientific information that existed regarding efficacy, accuracy, validity, utility, cost effectiveness, and limitations of portable equipment, but there was enough information to warrant a practice parameter paper to review the current knowledge base, at the time, regarding PM in the assessment of OSA (Standards of Practice Committee. *Chest* 1994; 17:372). The use of PM was not supported in that document.

In the subsequent decade, many additional studies emerged on the utility of HSAT in diagnosing OSA. By the

early 2000s, this topic had become very controversial, with strongly held opinions by the proponents of HSAT and its opponents. In 2003, a systematic review sponsored by the ACCP, the American Academy of Sleep Medicine, and the American Thoracic Society, found that the evidence in the literature at that time did not support the use of PM in the unattended setting for the diagnosis of OSA (Flemons et al. *Chest* 2003; 124:1543; Chesson et al. *Chest* 2003; 26:907).

Also raised were several secondary questions regarding PM, including the reproducibility of PM, the failure rate and need for retesting, the cost-benefit analysis, and the appropriate type of patient best suited for PM.

In 2004, as a result of that review, CMS determined that only polysomnography done in a facility-based sleep laboratory be used to identify patients with OSA. CMS then received a request to modify this decision to include the use of portable multichannel HSAT devices as an alternative to facility-based polysomnography in the evaluation of OSA. Despite this, CMS reported their

final decision in April 2005. CMS found that the evidence at that time was not adequate to support and, hence, reimburse for, the use of unattended portable multichannel sleep testing adequate for the diagnosis of OSA and the prescription of CPAP.

Just a few years later, in March 2007, at the request of the American Academy of

Otolaryngology-Head and Neck Surgery, CMS agreed to open up the issue and review it again. Some observers noted that the rapid rise

in Medicare reimbursements for sleep studies—\$62 million in 2001 to \$215 million in 2005—was a concern. It also was recognized that several large organizations, such as Kaiser Permanente and some Veterans Administration hospitals, reported using PM successfully in the diagnosis of OSA and treatment with CPAP. A long review process followed, involving expert review of the medical literature and written public opinion. The ACCP provided written comments based on feedback from members of the ACCP Sleep Institute and Sleep Medicine NetWork. Additionally, an open public hearing was held by an expert panel at

CMS headquarters in Baltimore, MD, on September 12, 2007.

On March 13, 2008, a decision memo was issued by CMS (CAG-00093R2) that, for the first time, allowed CPAP coverage based on the results of an HSAT. After receiving commentary from the ACCP and many other national organizations, the final national coverage determination (NCD) memo was posted in October and contained several specific provisions for reimbursement that will change the practice of sleep medicine (www.cms.hhs.gov/transmittals/downloads/R96NCD.pdf).

The NCD placed an emphasis on providing quality service to the patient before and after the sleep study in the treatment of OSA and not just on interpretation of the sleep study. This NCD dictated several new stipulations that determined the rules for CPAP reimbursement from the four durable medical equipment Medicare administrative carriers (DME MACs). The good news is that the regulations from all four are exactly the same.

There are some key features of which physicians who care for patients with

Continued on following page

Sleep Institute®

American College of Chest Physicians

Sponsored Courses

January 22 - 25, 2009

Sleep Medicine 2009
Scottsdale, AZ

January 24 - 25, 2009

Sleep Educator Conference 2009
Phoenix, AZ

February 27 - 28, 2009

Eliminating Borders: STS/ACCP
Multidisciplinary Evaluation of
Pulmonary/Thoracic Issues
Lake Tahoe, CA

April 3 - 5, 2009

Celebration of Pediatric
Pulmonology 2009
Scottsdale, AZ

April 24 - 26, 2009

Ultrasonography: Fundamentals
in Critical Care
Ft. Lauderdale, FL

August 21 - 24, 2009

ACCP Sleep Medicine Board
Review 2009
Phoenix, AZ

August 21 - 25, 2009

ACCP Critical Care Medicine
Board Review 2009
Phoenix, AZ

August 25, 2009

Lung Pathology 2009
Phoenix, AZ

August 25, 2009

Mechanical Ventilation 2009
Phoenix, AZ

August 25, 2009

ABIM Critical Care Medicine SEP Module
Phoenix, AZ

August 25, 2009

ABIM Pulmonary Disease SEP Module
Phoenix, AZ

August 26 - 30, 2009

ACCP Pulmonary Medicine
Board Review 2009
Phoenix, AZ

October 31 - November 5, 2009

CHEST 2009
San Diego, CA

ACCP Simulation Center for Advanced Clinical Education

Northbrook, Illinois

February 2 - 5, 2009

iStan Basic and Advanced Course
Northbrook, IL

February 13 - 15, 2009

Critical Care Fundamentals
Northbrook, IL

February 20 - 22, 2009

Bronchoscopy Skills
Northbrook, IL

March 6 - 8, 2009

Difficult Airway Management
Northbrook, IL

May 4 - 7, 2009

Human Patient Simulator (HPS):
Basic and Advanced Course
Northbrook, IL

November 9 - 12, 2009

Emergency Care Simulator (ECS):
Basic and Advanced Course
Northbrook, IL

Endorsed Courses

January 22 - 24, 2009

ACCP Italian Chapter Biannual Meeting
Paestrum, Italy

March 7 - 9, 2009

Update on Asthma and COPD
Lucknow, India

March 22 - 23, 2009

IX ACCP Course/ XXIII Central American
and the Caribbean Meeting of Pulmonology
and Thoracic Surgery
San José, Costa Rica

March 24 - 27, 2009

29th International Symposium on Intensive
Care and Emergency Medicine
Brussels, Belgium

April 3 - 5, 2009

SLEEPCON 2009
Chennai, India

April 13 - 17, 2009

XVIII Congress of the Mexican Society of
Pulmonology and Thoracic Surgery
Veracruz, Mexico

May 9 - 10, 2009

University Hospital of Lung Diseases
Tirania, Albania

■ ACCP-Sponsored Courses
■ ACCP-Endorsed Courses

AMERICAN COLLEGE OF CHEST PHYSICIANS

2009
EducationCalendar

Learn more about ACCP-sponsored and ACCP-endorsed educational courses.
www.chestnet.org/education/calendar.php
(800) 343-2227 or +1 (847) 498-1400

AMERICAN COLLEGE OF
CHEST
PHYSICIANS®

Continued from previous page

OSA should be aware. Initially, the patient must have a face-to-face clinical evaluation by the treating physician prior to the sleep test to assess the patient for OSA. This evaluation needs to include the following elements:

History

- ▶ Signs and symptoms of sleep-disordered breathing, including snoring, daytime sleepiness, observed apneas, choking or gasping during sleep, and morning headaches

- ▶ Duration of symptoms

- ▶ Validated sleep hygiene inventory, such as the Epworth sleepiness scale

Physical Exam

- ▶ Focused cardiopulmonary and upper airway system evaluation

- ▶ Neck circumference

- ▶ Body mass index (BMI)

The initial CPAP coverage for adults could occur if OSA was diagnosed using a clinical evaluation and a positive polysomnogram was performed either in a sleep laboratory or by unattended home sleep monitoring using a type 2, 3, or 4 device (measuring at least three channels that must include respiratory effort and nasal pressure or airflow). The threshold apnea-hypopnea index (AHI) or respiratory disturbance index (RDI) must be ≥ 15 events per hour of sleep (AHI) or continuous monitoring (RDI) or ≥ 5 events, with documented symptoms of excessive daytime sleepiness; impaired cognition, mood disorders or insomnia; or documented hypertension, ischemic heart disease, or history of stroke. This initial coverage for CPAP is initially limited to a 12-week period.

Extending the CPAP prescription beyond 12 weeks is now dependent on a mandatory face-to-face reevaluation of the patient that must occur between 31 and 90 days. CPAP will be subsequently covered only for those beneficiaries who fulfill the following two requirements: (1) the OSA must have improved as a result of CPAP treatment, which can be documented simply by a physician interview, and (2) objective evidence of adherence to use of the CPAP device must be reviewed by the treating physician and available upon request. Adherence to therapy is defined as use of CPAP 4 h per night or more on 70% of nights during a consecutive 30-day period anytime during the first 3 months of initial usage. The responsibility for the

objective compliance data is placed upon the DME vendor filing the claim with the regional DME MAC. This has already resulted in DME vendors making arrangements for the download of the data with the patient directly or working out an arrangement with nearby prescribing physicians.

This becomes complicated for patients who have not adhered to treatment. Beneficiaries who fail the initial 12-week trial are eligible to requalify for CPAP devices. However, they must undergo both a new face-to-face clinical reevaluation by the treating physician, to determine the etiology of the failure to respond to CPAP therapy, and a repeat sleep test in a facility-based setting (type 1 study). If the physician decides to switch to a bilevel device, only a new prescription is needed. The prescription can be mailed to the patient; however, the patient will have to demonstrate the treatment adherence behavior necessary to complete the compliance statement for a respiratory assist device.

This, however, is only half of the story. There is another aspect necessary for understanding reimbursement when an HSAT device is involved in diagnosing OSA. So far, the discussion has concerned what is required for a patient to receive reimbursement for a CPAP prescription. The DME MACs control reimbursement for CPAP but have nothing to do with payment for the HSAT. Payment to the physician and facility for performing and interpreting an HSAT is governed by a different set of rules. Payment for the HSAT is governed by whichever regional carrier is responsible for the patient being treated, and the rules are covered by 1 of 14 local coverage determinations (LCDs). These rules vary significantly among the various local carriers and are not tied to all the specifics of the NCD. For example, CIGNA is one carrier that has decided some issues on its own (www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0158_coveragepositioncriteria_obstructive_sleep_apnea_diag_trtment_svc.pdf).

CIGNA refused to cover type 4 devices, including WatchPAT (Itamar Medical; Framingham, MA), which was allowed by the NCD for CPAP coverage. This carrier also determined that split-night studies will be covered only if the AHI is >20 during the diagnostic portion of the test. This can be

determined in as little as 2 h of recording time; recall that the old "2-h rule" (2 h of actual sleep required to determine an AHI) is now dismissed by virtually all carriers. Some clinicians initiate CPAP at an AHI as low as 5 because some carriers will not cover a second sleep study for titration.

The bottom line is that the DME MAC NCD can be fulfilled with one set of rules to provide coverage for the CPAP prescription, but there may be a different set of rules governing reimbursement for the actual sleep studies performed. Each physician should consult the Web site of the Medicare carrier for their region to be aware of specific rules.

Some final interesting issues are apparent that the ACCP and other societies may need to address. These rulings may not lead to fewer facility-based studies. The standard of care still dictates the performance of some type of titration study, which, if conducted in the sleep lab, is actually more costly after a home sleep test (HST) than a split-night study alone. Note that comments about auto-PAP titration are conspicuously absent from the NCD and DME LCD. It would be difficult to cover, given that there is no unique auto-PAP code.

Even though the burden of documentation will be on the DME vendor, it will inevitably fall back to the physicians who interpret and order the studies. One also wonders if there might be a

minimum quota for HST, but the pressure to perform more HSTs may actually come from private payers. This may result in many labs being forced to offer HST at a loss, as CMS proposes reimbursement to be near \$200.

There is no national standardization for the LCDs, and this will result in a complex playing field and possible frequent denials of coverage. Lastly, the Office of Inspector General at the US Department of Health and Human Services has announced that it will launch a campaign to audit sleep centers throughout the country to confirm that charges are legitimate. It is certain that some ACCP members will have their billing/medical records reviewed by the Office of Inspector General investigators.

For ACCP members, the good news is that the ACCP, through the ACCP Sleep Institute, the Sleep Medicine Network, the Practice Management Committee, the Government Relations Committee, and the ACCP staff supporting each of these committees, is actively involved in monitoring all these developments on behalf of its members. The ACCP has the ability to respond rapidly to any changes affecting the quality of care we provide our patients. ■

Dr. Peter C. Gay, FCCP
Mayo Clinic
Rochester, MN

Career Initiative Unveiled at CHEST 2008

In a new education initiative aimed at promoting careers in pulmonary, critical care, and/or sleep medicine, the American College of Chest Physicians invited medical students and residents in the northeast region of the county to attend CHEST 2008 in Philadelphia.

The ACCP's primary goal was to provide students and residents an opportunity to attend the ACCP annual meeting and hear from leading experts in these fields. Students and residents enjoyed complimentary registration and were able to participate in a rich educational day of programming, consisting of an

overview and orientation to pulmonary, critical care, and sleep medicine career opportunities; scientific abstract presentation sessions; complimentary lunch in the exhibit hall; poster grand rounds; and hands-on clinical education in the Simulation Center. Students were also invited to attend the CHEST Challenge Championship and Awards Reception as an educational and networking opportunity.

Based on the success of this year's program, medical students and residents on the West coast will be invited to attend a similar program at CHEST 2009 in San Diego, CA. ■

Simulation Education. Real Results.

ACCP
Simulation
Center
for Advanced
Clinical Education
Northbrook, Illinois

Now
Open!



Attend a hands-on, clinical learning experience:

- Current standards of practice
- Patient safety
- Evidence-based patient care
- Formative assessment procedures

Experienced clinicians will help you apply skills and make a real impact on your practice.

Register now.
www.chestnet.org/simulation

AMERICAN COLLEGE OF
CHEST
PHYSICIANS®

METI
Medical Education Technologies, Inc.

Don't Miss These Sessions

iStan: Basic and Advanced Course

February 2-5, 2009
This 4-day course instructs learners in the essential aspects of setup, operation, and maintenance of the iStan.

Critical Care Fundamentals

February 13-15, 2009
This 3-day multimodal course will utilize various degrees of simulation to offer experiential learning in domains, including ventilator management, hemodynamic monitoring, and management of a critically ill patient.

Bronchoscopy Skills

February 20-22, 2009
This 3-day course will expose participants to the cognitive and psychomotor skills involved in utilizing bronchoscopy effectively in clinical practice.

Difficult Airway Management

March 6-8, 2009
This 3-day simulation-enhanced workshop will provide hands-on experience with preparation, teamwork, and tools to manage common and complex airway situations.

Human Patient Simulator (HPS):

Basic and Advanced Course

May 4-7, 2009
This 4-day course instructs learners in the essential aspects of setup, operation, and maintenance of the human patient simulator.

Emergency Care Simulator (ECS): Basic and Advanced Course

November 9-12, 2009
This 4-day course instructs learners in the essential aspects of setup, operation, and maintenance of the emergency care simulator.

BROVANA for patients with COPD requiring maintenance therapy

Bob's back...

Breathing



Not an actual patient.

*BROVANA has not been demonstrated to have an impact on progression of disease or survival of patients with COPD.

† Clinical trial A was one of two identical 12-week, double-blind, placebo- and active-controlled, randomized, multicenter, parallel-group studies that included a comparison of BROVANA 15 mcg twice daily with placebo.

The results from clinical trial B were similar to clinical trial A.

Please see Brief Summary of complete Prescribing Information, including Boxed Warning, on following page.

BROVANA is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.

Important Safety Information

Long-acting beta₂-adrenergic agonists may increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta₂-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to arformoterol (a long-acting beta₂-adrenergic agonist), the active ingredient in BROVANA.

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers.

BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.

BROVANA should not be used in conjunction with other inhaled, long-acting beta₂-agonists. BROVANA should not be used with other medications containing long-acting beta₂-agonists. Patients who have been taking inhaled short-acting beta₂-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

As with other inhaled beta₂-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta₂-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.

BROVANA, as with other beta₂-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

The most common adverse events reported in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

References: 1. BROVANA (prescribing information). Marlborough, MA: Sepracor Inc; August 2008.

2. Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. *Clin Ther*. 2007;29(2):261-278. 3. Data on file, Sepracor Inc. CSR-091-050, Table 14.2.11.2.

 SEPRACOR, and BROVANA are registered trademarks of Sepracor Inc.

©2008 Sepracor Inc., Marlborough, MA 01752 All rights reserved.
11/08 BRO138-08


better, living better*

with BROVANA just twice a day

Sustained relief and twice-daily dosing help COPD patients get back to daily living

Sustained effective relief for a full 12 hours¹

Mean change in FEV₁ over time at 12 weeks: clinical trial A^{2,3}



†100-mL increase from study baseline in mean FEV₁ at 12 hours (Week 12), while the placebo group had a 60-mL decrease.³ Overall efficacy was maintained throughout the 12-week trial. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV₁ improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.²

Relief that works within minutes

6.7-minute median time to onset (15% increase in FEV₁)¹

- BROVANA is not indicated for the treatment of acute episodes of bronchospasm. Patients on BROVANA should always have access to rescue therapy

Well tolerated

- Patients receiving BROVANA 15 mcg twice daily experienced an incidence of adverse events (AEs) comparable with placebo¹
- Most common AEs were pain, chest pain, back pain, diarrhea, and sinusitis

Nebulized bronchodilator therapy for patients with COPD

Have your patients experience BROVANA

For samples, ask your Sepracor representative



Brovana¹⁵
mcg
(arformoterol tartrate) Inhalation Solution

Get them back into daily living

NETWORKS

JUPITER, Allergen Immunotherapy, Critical Care Education

Cardiovascular Medicine and Surgery

The JUPITER trial (Justification for the Use of Statins in Prevention: An Interventional Trial Evaluating Rosuvastatin), a heavily publicized trial, screened 89,890 subjects for cardiovascular risk factors, and enrolled 17,802 subjects with the following entry criteria constellation: men 50 or women 60 years of age or older, without history of CAD,

LDL-cholesterol level of < 130 mg/dL, and high-sensitivity C-reactive protein (CRP) level of ≥ 2.0 mg/L or more.

Subjects received either 20 mg of rosuvastatin or placebo. Primary endpoint was the composite of MI, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. The trial was designed for a follow-up of 4 years but was prematurely

stopped after 1.9 years, due to a significant reduction in the primary endpoint in the treatment group (142 vs 251 events in the placebo group). The authors argue rosuvastatin should be considered even in healthy, normolipidemic individuals with elevated high sensitivity CRP.

There may be several concerns to consider: (1) The absolute (not relative) risk reduction was 1.8 to 0.9%, thus 120

participants needed to be treated for 1.9 years to prevent an event. This would amount to roughly \$500,000 per life saved. (2) The study was already targeting people with elevated BMI and an increased incidence of metabolic syndrome. Abdominal obesity and insulin resistance were probably prevalent in this study group; they alone could account for the therapy success. The higher levels of glycosylated hemoglobin and incidence of diabetes in the rosuvastatin group are disconcerting; longer follow-up may have been helpful.

JUPITER raises interesting questions about the role of biomarkers in cardiac prevention, and how aggressive we should become in the CV preventive arena. It remains to be seen if we should alter our current practice.

Dr. Thomas Behrenbeck, FCCP
NetWork Chair

Further Reading

- Ben-Yehuda. *JACC* 2007; 49:2139-2141
Hlatky. *N Engl J Med* 2008; 359:2280-2282
Kinlay. *JACC* 2007; 49:2003-2009
Lemieux et al. *Arterioscler Thromb Vasc Biol* 2001; 21:961-967
Ridker et al. *N Engl J Med* 2008; 359:2197-2207
Tracy. *Arterioscler Thromb Vasc Biol* 2001; 21:881-883

Clinical Pulmonary Medicine

Allergen-specific immunotherapy, which involves repeated administration of an allergen to IgE-sensitized allergic individuals to induce clinical and immunologic tolerance (Alvarez-Cuesta, et al. *Allergy* 2006; 61:1) is regarded as controversial due to risk of severe anaphylaxis (Lockey et al. *J Allergy Clin Immunol* 1987; 76:660; Bousquet et al. *J Allergy Clin Immunol* 1989; 83:797).

Although allergen avoidance and pharmacotherapy form the basis of asthma treatment, immunotherapy is effective in reducing symptoms induced by dust mite, animal dander, cockroach, pollen, and mold (Bousquet et al. *Allergy* 1998; 53:1). Recent Cochrane analysis (Abramson et al. The Cochrane Database of Systematic Reviews 2008, Issue 4. Art No. CD001186. DOI: 10.1002/14651858.CD001186) of 3,506 participants (3,188 asthmatics) demonstrated significant reduction in asthma symptoms and medications, and improvement in bronchial hyperresponsivity (BHR) following immunotherapy.

NHLBI recommends immunotherapy for patients with allergic asthma who need low to medium dose inhaled corticosteroids (NIH Publication no. 08-4051, available from www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm). Notably, patients with exacerbations requiring hospitalizations or intubations (Amin et al. *J Allergy Clin Immunol* 2006; 117:169), FEV₁ <70% predicted (Rank and Li. *Mayo Clin Proc* 2007; 82:1119), or unstable asthma receiving long-term oral

Continued on following page

BROVANA® (arformoterol tartrate) Inhalation Solution 15 mcg*/2 mL *potency expressed as arformoterol FOR ORAL INHALATION ONLY BRIEF SUMMARY

WARNING: Long-acting beta₂-adrenergic agonists may increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta₂-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to arformoterol (a long-acting beta₂-adrenergic agonist), the active ingredient in BROVANA (see WARNINGS).

INDICATIONS AND USAGE BROVANA (arformoterol tartrate) Inhalation Solution is indicated for the long term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only. **CONTRAINDICATIONS** BROVANA (arformoterol tartrate) Inhalation Solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. **WARNINGS** Long-acting beta₂-adrenergic agonists may increase the risk of asthma-related death. A 28-week, placebo-controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34). The increased risk of asthma-related death may represent a class effect of the long-acting beta₂-adrenergic agonists, including BROVANA. No study adequate to determine whether the rate of asthma-related death is increased in patients treated with BROVANA has been conducted. Clinical studies with racemic formoterol (Foradil® Aerolizer™) suggested a higher incidence of serious asthma exacerbations in patients who received racemic formoterol than in those who received placebo. The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups. **The studies described above enrolled patients with asthma. Data are not available to determine whether the rate of death in patients with COPD is increased by long-acting beta₂-adrenergic agonists. BROVANA is indicated for the long term, twice daily (morning and evening) maintenance treatment for bronchoconstriction in chronic obstructive pulmonary disease (COPD), and is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. The use of BROVANA in this setting is inappropriate. BROVANA should not be used in children as the safety and efficacy of BROVANA have not been established in pediatric patients. BROVANA should not be used in conjunction with other inhaled, long-acting beta₂-agonists. BROVANA should not be used with other medications containing long-acting beta₂-agonists. When beginning treatment with BROVANA, patients who have been taking inhaled, short-acting beta₂-agonists on a regular basis (eg, four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. Paradoxical Bronchospasm** As with other inhaled beta₂-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted. **Deterioration of Disease** COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If BROVANA no longer controls the symptoms of bronchoconstriction, or the patient's inhaled, short-acting beta₂-agonist becomes less effective or the patient needs more inhalation of short-acting beta₂-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of BROVANA beyond the recommended 15 mcg twice daily dose is not appropriate in this situation. **Cardiovascular Effects** BROVANA, like other beta₂-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of BROVANA at the recommended dose, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. BROVANA, as with other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension (see **PRECAUTIONS, General**). **Immediate Hypersensitivity Reactions** Immediate hypersensitivity reactions may occur after administration of BROVANA as demonstrated by cases of anaphylactic reaction, urticaria, angioedema, rash and bronchospasm. **Do Not Exceed Recommended Dose** Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. As with other inhaled beta₂-adrenergic drugs, BROVANA should not be used more often, at higher doses than recommended, or with other long acting beta-agonists. **PRECAUTIONS, General** BROVANA (arformoterol tartrate) Inhalation Solution should not be used to treat acute symptoms of COPD. BROVANA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. When prescribing BROVANA, the physician should also provide the patient with an inhaled, short-acting beta₂-agonist for treatment of COPD symptoms that occur acutely, despite regular twice-daily (morning and evening) use of BROVANA. Patients should also be cautioned that increasing inhaled beta₂-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. BROVANA, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and/or diastolic blood pressure, pulse rate and electrocardiograms have been seen infrequently in individual patients in controlled clinical studies with arformoterol tartrate. Doses of the related beta₂-agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. Beta-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Clinically significant changes in blood glucose and/or serum potassium were infrequent during clinical studies with long-term administration of BROVANA at the recommended dose. **Information for Patients** Patients should be instructed to read the accompanying Medication Guide with each new prescription and refill. Patients should be given the following information: Patients should be informed that long-acting beta₂-adrenergic agonists may increase the risk of asthma-related death. BROVANA is not indicated to relieve acute respiratory symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting, beta₂-agonist (the health-care provider should prescribe the patient with such medication and instruct the patient in how it should be used). Patients should be instructed to seek medical attention if their symptoms worsen, if BROVANA treatment becomes less effective, or if they need more inhalations of a short-acting beta₂-agonist than usual. Patients should not inhale more than one dose at any one time. The daily dosage of BROVANA should not exceed one vial (15 mcg) by inhalation twice daily (30 mcg total daily dose). Patients should be informed that treatment with beta₂-agonists may lead to adverse events which include palpitations, chest pain, rapid heart rate, tremor, or nervousness. Patients should be instructed to use BROVANA by nebulizer only and not to inject or swallow this inhalation solution. Patients should protect BROVANA single-use low-density polyethylene (LDPE) vials from light and excessive heat. The protective foil pouches should be stored under refrigeration between 2°C and 8°C (36°-46°F). They should not be used after the expiration date stamped on the container. Patients should be instructed that once the foil pouch is opened, the contents of the vial should be used immediately and to discard any vial if the solution is not colorless. The drug compatibility (physical and chemical), efficacy and safety of BROVANA when mixed with other drugs in a nebulizer have not been established. Women should be advised to contact their physician if they become pregnant or if they are nursing. It is important that patients understand how to use BROVANA appropriately and how it should be used in relation to other medications to treat COPD they are taking. **Drug Interactions** If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated. When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered. Dosage adjustments of BROVANA are not necessary when the drug is given concomitantly with potent CYP2D6 inhibitors. Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists. The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics. BROVANA, as with other beta₂-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias. The concurrent use of intravenously or orally administered methylxanthines (eg, aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated. In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA-treated subjects received concomitant theophylline at study entry. In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA-treated subjects received concomitant theophylline at study entry. In these trials, heart rate and systolic blood pressure were approximately 2-3 bpm and 6-8 mm Hg higher, respectively, in subjects on concomitant theophylline compared with the overall population. Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. **Carcinogenesis, Mutagenesis, Impairment of Fertility** Long-term studies were conducted in mice using oral administration and rats using inhalation administration to evaluate the carcinogenic potential of arformoterol. In a 24-month carcinogenicity study in CD-1 mice, arformoterol caused a dose-related increase in the incidence of uterine and cervical endometrial stromal polyps and stromal cell sarcoma in female mice at oral doses of 1 mg/kg and above (AUC exposure approximately 70 times adult exposure at the maximum recommended daily inhalation dose). In a 24-month carcinogenicity study in Sprague-Dawley rats, arformoterol caused a statistically significant increase in the incidence of thyroid gland C-cell adenoma and carcinoma in female rats at an inhalation dose of 200 mcg/kg (AUC exposure approximately 130 times adult exposure at the maximum recommended daily inhalation dose). There were no tumor findings with an inhalation dose of 40 mcg/kg (AUC exposure approximately 55 times adult exposure at the maximum recommended daily inhalation dose). Arformoterol was not mutagenic or clastogenic in the following tests: mutagenicity tests in bacteria, chromosome aberration analyses in mammalian cells, and micronucleus test in mice. Arformoterol had no effects on fertility and reproductive performance in rats at oral doses up to 10 mg/kg (approximately 2700 times the maximum recommended daily inhalation dose in adults on a mg/m² basis). **Teratogenic Effects. Pregnancy Category C** Arformoterol has been shown to be teratogenic in rats based upon findings of omphalocele (umbilical hernia), a malformation, at oral doses of 1 mg/kg and above (AUC exposure approximately 370 times adult exposure at the maximum recommended daily inhalation dose). Arformoterol has been shown to be teratogenic in rabbits based upon findings of malpositioned right kidney, a malformation, at oral doses of 20 mg/kg and above (AUC exposure approximately 8400 times adult exposure at the maximum recommended daily inhalation dose). There are no adequate and well-controlled studies in pregnant women. BROVANA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Use in Labor and Delivery** There are no human studies that have investigated the effects of BROVANA on preterm labor or labor at term. Because beta-agonists may potentially interfere with uterine contractility, BROVANA should be used during labor and delivery only if the potential benefit justifies the potential risk. **Nursing Mothers** In reproductive studies in rats, arformoterol was excreted in the milk. It is not known whether arformoterol is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BROVANA is administered to a nursing woman. **Pediatric** BROVANA is approved for use in the long term maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. This disease does not occur in children. The safety and effectiveness of BROVANA in pediatric patients have not been established. **Geriatric** Of the 873 patients who received BROVANA in two placebo-controlled clinical studies in adults with COPD, 391 (45%) were 65 years of age or older while 96 (11%) were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Among subjects age 65 years and older, 129 (33%) received BROVANA at the recommended dose of 15 mcg twice daily, while the remainder received higher doses. ECG alerts for ventricular ectopy in patients 65 to ≥ 75 years of age were comparable among patients receiving 15 mcg twice daily, 25 mcg twice daily, and placebo (3.9%, 5.2%, and 7.1%, respectively). A higher frequency (12.4%) was observed when BROVANA was dosed at 50 mcg once daily. The clinical significance of this finding is not known. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. **ADVERSE REACTIONS Experience in Adult Patients with COPD** Of the 1,456 COPD patients in the two 12-week, placebo-controlled trials, 288 were treated with BROVANA (arformoterol tartrate) inhalation solution 15 mcg twice daily and 293 were treated with placebo. The numbers and percent of patients who reported adverse events were comparable in the 15 mcg twice daily and placebo groups. Adverse events for which the rates in the BROVANA 15-mcg twice-daily group was equal to or greater than 2% and greater than that for the placebo group were (BROVANA and placebo rates, respectively) pain (8%, 5%), chest pain (7%, 6%), back pain (6%, 2%), diarrhea (6%, 4%), sinusitis (5%, 4%), leg cramps (4%, 2%), dyspnea (4%, 2%), rash (4%, 2%), flu syndrome (3%, 1%), peripheral edema (3%, 2%), lung disorder (2%, 1%). Ten adverse events demonstrated a dose relationship: asthenia, fever, bronchitis, COPD, headache, vomiting, hyperkalemia, leukocytosis, nervousness, and tremor. Overall, the frequency of all cardiovascular adverse events for BROVANA in the two placebo-controlled trials was low and comparable to placebo (6.9% in BROVANA 15-mcg twice-daily and 13.3% in the placebo group). There were no frequently occurring specific cardiovascular adverse events for BROVANA (frequency $\geq 1\%$ and greater than placebo). The rate of COPD exacerbations was also comparable between the BROVANA 15-mcg twice-daily and placebo groups, 12.2% and 15.1%, respectively. Other adverse reactions that may occur with selective beta₂-adrenoceptor agonists, such as BROVANA, include angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis, and insomnia. **OVERDOSSAGE** The expected signs and symptoms associated with overdosage of BROVANA (arformoterol tartrate) Inhalation Solution are those of excessive beta₂-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms listed under **ADVERSE REACTIONS**, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of BROVANA. Treatment of overdosage consists of discontinuation of BROVANA together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of BROVANA. Cardiac monitoring is recommended in cases of overdosage. Clinical signs in dogs included flushing of the body surface and facial area, reddening of the ears and gums, tremor, and increased heart rate. A death was reported in dogs after a single oral dose of 5 mg/kg (approximately 4500 times the maximum recommended daily inhalation dose in adults on a mg/m² basis). Death occurred for a rat that received arformoterol at a single inhalation dose of 1600 mcg/kg (approximately 430 times the maximum recommended daily inhalation dose in adults on a mg/m² basis).

Continued from previous page

glucocorticoids (Reid et al. *J Allergy Clin Immunol* 1993; 92:6) are not suitable for immunotherapy, as they are at risk for severe bronchospasm. Evaluation of sensitization is a prerequisite.

While subcutaneous immunotherapy is the established treatment, sublingual immunotherapy is a viable alternative, since no serious reactions have been reported, and self-administration obviates frequent physician visits for injections (Mungan et al. *Ann Allergy Asthma Immunol* 1999; 82:485).

Bronchial Thermoplasty

Increased airway smooth-muscle mass is observed in patients with severe or fatal asthma (Carroll et al. *Am Rev Respir Dis* 1993; 147:405). Bronchial thermoplasty (BT) delivers radiofrequency energy to the bronchial wall through a catheter with expandable four-arm-basket via bronchoscopy. While airway cells are susceptible to heat injury, complete anatomic reconstitution occurs except for smooth muscle (Cox et al. *Eur Respir J* 2004; 24:659).

In the Asthma the Intervention Trial (Cox et al. *N Engl J Med* 2007; 356:1327), where 110 moderate to severe-persistent asthmatics were randomized to standard medical

care with and without BT, those who received BT had fewer exacerbations; improved peak flow rates; more symptom-free-days; and better symptom scores, quality of life, and asthma control questionnaire responses. As the study was not blinded, improved subjective outcomes with BT that did not correspond to objective measurements (FEV₁, BHR) are a concern, and results comparing BT with sham bronchoscopy are eagerly awaited.

Asthma treatment is evolving beyond steroids and bronchodilation and into disease-modifying interventions with immunotherapy and BT.

Dr. Pyng Lee, FCCP

NetWork Steering Committee Member

Critical Care

CHEST 2008 provided an excellent opportunity for the Critical Care NetWork to reflect on a very successful year. The NetWork meeting was highlighted by a presentation by Dr. Kay Guntupalli, FCCP, ACCP President-Elect and recipient of the 2007-2008 Distinguished Scholar Award, for her project, "Development and Validation of the Educational Materials for Use by the Critical Care Health-care Team and Patient/Family for Use in the Critical Care Units."

The NetWork also sponsored a wide variety of outstanding educational offerings.

The ACCP is sponsoring several critical care courses at its Simulation Center for Advanced Clinical Education in Northbrook, IL, in early 2009. For more information or to register, visit www.chestnet.org/simulation/programs.php.

We would like to invite interested members to join one of the six subcommittees that are responsible for the majority of our NetWork activities. Please visit www.chestnet.org/networks/critical_care/index.php for more information.

We are working very hard to increase your resources on the Critical Care NetWork Web page, and we need your help!

We are looking for individuals who are interested in submitting clinical vignettes, images, and tracings for the NetWork Online Puzzler.

Submissions should be under 800 words and include a summary of relevant clinical information and a brief discussion of one to two key points with up to five references. Contact me at alexander.niven@us.army.mil with submissions or questions.

LTC Alexander Niven, MC, USA, FCCP
NetWork Chair

This Month in CHEST: Editor's Picks

BY DR. RICHARD S. IRWIN, FCCP
Editor in Chief, CHEST

► **Survival for Patients With HIV Admitted to the ICU Continues To Improve in the Current Era of Combination Antiretroviral Therapy.** By Dr. K. Powell, et al.

► **The Effects of Flexible Bronchoscopy on Mechanical Ventilation in a Pediatric Lung Model.** By Dr. D. Hsia, et al.

► **A Phase 3, Randomized, Double-Blind, Study To Assess the Efficacy and Safety of Fospropofol Disodium Injection for Moderate Sedation in Patients Undergoing Flexible Bronchoscopy.** By Dr. G. A. Silvestri, FCCP, et al.

► **INTERACTIVE PHYSIOLOGY GRAND ROUNDS Assessment of Pleural Pressure in the Evaluation of Pleural Effusions.** By Dr. D. Feller-Kopman, et al (new series including online animation).

► **RECENT ADVANCES IN CHEST MEDICINE Critical-Illness-Related Corticosteroid Insufficiency.** By Dr. P. E. Marik, FCCP.



www.chestjournal.org

Specialty Medicine. Specialty Codes.

NOW AVAILABLE!

Coding for Chest Medicine 2009

PULMONARY CRITICAL CARE SLEEP

New! 13th Edition

For a coding resource as precise and specialized as the medicine you practice, turn to *Coding for Chest Medicine 2009*. The updated 13th edition includes detailed coding information for pulmonary, critical care, and sleep medicine, with a new chapter on rapid response teams. This resource is perfect for physicians, nonphysician providers, and administrative staff.

Member \$125*
Nonmember \$160*
Product #1132

*plus shipping and handling

Act Now!

www.chestnet.org
(800) 343-2227 or (847) 498-1400



Critical Training in Critical Care

Ultrasonography: Fundamentals in Critical Care

APRIL 24-26, 2009

HYATT REGENCY BONAVENTURE
FT. LAUDERDALE, FL

Don't miss this robust educational experience in ultrasound training, featuring hands-on skill-building opportunities with live patient models. The three critical components of ultrasonography—knowledge base, image interpretation, and image acquisition—will be covered in depth, so you develop proficiency in this emerging field.

Register Early and Save

Visit our Web site for details, or contact ACCP Customer Relations.

www.chestnet.org
(800) 343-2227 or +1 (847) 498-1400



CLASSIFIEDS

Also available at www.elsevierhealthcareers.com

PROFESSIONAL OPPORTUNITIES

PULMONOLOGY/CRITICAL CARE OPPORTUNITY

Pulmonology/Critical Care group is seeking an Associate in one of the fastest growing cities in the nation, Las Cruces, New Mexico. Must be board eligible/certified. Competitive first year income guarantee. Excellent marketing and relocation assistance. Strong primary care referral base. Located in charming university community, Las Cruces offers 350 days a year of sunshine, warm weather, and low cost of living. Surrounding mountain and desert landscapes provide for great outdoor recreation activities. Contact Sam Benevento, Director of Physician Recruitment, Memorial Medical Center, by phone: 575-532 7404, or e-mail: samyeann.benevento@lpnt.net

Marietta Pulmonary Medicine Suburban Atlanta

Well-established, busy 11-physician single-specialty Pulmonary practice in suburban Atlanta, Georgia, looking for one or more BC/BE Pulmonary/Critical Care physicians. Sleep certification is a plus. Practice includes all aspects of pulmonary medicine, including critical care, sleep medicine, out-patient clinic, pulmonary rehab and clinical research. Practice located at two large acute-care hospitals, with one being the busiest ER in Georgia, and also rounds at a nearby long term acute care hospital. Competitive salary with bonus potential, generous benefits package and malpractice coverage. Fax CV to: 770-792-1738.

Sixth Physician for Pulmonary Group

Pulmonary/Sleep Medicine/Critical Care. Sixth physician for Pulmonary Group. Eastern Connecticut. One hospital coverage and Sleep Center. Near to shore. Easy access to New York and Boston. Many cultural and recreational activities. Partnership available. Send CV to Chest #95, P.O. Box 996, Abingdon, MD 21009.

Intensivist

NEW YORK – Desirable Coastal Long Island Community. Intensivist needed for new program at state of the art community hospital. Just a short drive or train ride to metropolitan area. Excellent schools and beautiful homes. Excellent salary and earning potential and full benefits. Submit CV to ffldcmd@hotmail.com

Pulmonary Critical Care Physician

BC/BE Pulmonary Critical Care Physician wanted for a large pulmonary, critical care private practice in Southeast Florida; large office and hospital practice including sleep medicine and intensivist program. Opening available in early 2009. Please reply to Chest # 92, P.O. Box 996, Abingdon, MD 21009.

Suburban Pittsburgh

Pulmonary and Sleep Medicine Physician needed in suburban Pittsburgh, PA. Excellent salary and fringe benefits. Equal Opportunity Employer. J-1 Visa consideration. Please send CV to Chest #84, P.O. Box 996, Abingdon, MD 21009.

BEAUTIFUL COAST OF MAINE BC/BE Pulmonologist


Multi-specialty community hospital seeks physician for outpatient, hospital and critical care. Belfast offers beautiful views of Penobscot Bay. Ideal for outdoor enthusiasts. Family oriented with excellent schools. Immediate availability. Contact Dan Bennett, Director of Operations, Waldo County General Hospital, PO Box 287, Belfast, ME 04915, 207-930-6741 E-mail: dbennett@wchi.com Website: www.wchi.com



THE
CHEST
FOUNDATION

Donate today!
www.chestfoundation.org

**Let's not pollute our ocean of air
like we polluted theirs.**



**AMERICAN
LUNG
ASSOCIATION®**
The Christmas Seal People®

Space contributed by the publisher as a public service.

Pulmonary Critical Care Opportunity Northern California

Sutter Medical Group (SMG) is seeking a BE/BC Pulmonary Critical Care physician in Auburn, CA. Good call schedule. Option for hospitalist work if desired.



SMG is a multi-specialty group of over 300+ members. SMG offers an income guarantee with shareholder track, generous compensation, benefits, and retirement package.

Sutter Auburn Faith Hospital is a medium sized hospital with a 24/7 hospitalist program, open ICU, high resolution CT scan, cardiac cath lab, full nuclear medicine department, bronchoscopy suites and a pulmonary function laboratory.

Auburn is centrally located in the Sierra Nevada foothills between Sacramento and Lake Tahoe. Auburn is close to shopping and restaurants, and offers a variety of outdoor activities.

Physician Recruitment
800-650-0625
916-643-6677 fax
develops@sutterhealth.org
www.sutterhealth.org

 **Sutter Health**
Sacramento Sierra Region
With You. For Life.

Northern California Hospitalist Opportunity

Sutter Medical Group is seeking a Hospitalist to join their successful expanding Hospitalist program in Auburn, CA. Candidate must have two years of recent experience doing procedures and be able to handle ICU coverage.

- 2-year shareholder track
- Generous compensation
- Competitive benefits package
- Excellent retirement package
- Wide variety of shifts available
- School system is one of the best in CA
- Great quality of life

Sutter Auburn Faith Hospital, has 95 beds, a 24/7 Hospitalist program, open ICU, high resolution CT scan, cardiac cath lab, full nuclear medicine department, bronchoscopy suites and a pulmonary function laboratory.

The community of Auburn is nestled in the Sierra Nevada Foothills approximately 35 miles northeast of Sacramento. Auburn is known for its family-oriented atmosphere and for its excellent schools. Residents enjoy year-round outdoor recreations such as golfing, hiking, biking, and white water rafting.

 **Sutter Health**
Sacramento Sierra Region

Physician Recruitment
800-650-0625
916-643-6677 fax
develops@sutterhealth.org
www.sutterhealth.org

2009 CLASSIFIEDS

**Chest Physician Rates
4 Column Classified Ads
From 1" to 12"
Sizes from 1/48th of a page
to a full page**

**For Deadlines and
More Information Contact:**
Rhonda Beamer
Walchi Tauber Group, Inc.
2225 Old Emmorton Road, Suite 201
Bel Air, MD 21015
443-512-8899 Ext 106
FAX: 443-512-8909
Email: rhonda.beamer@wt-group.com

Disclaimer


CHEST PHYSICIAN assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.

Treating GERD in Asthma Improved Lung Function

BY SUSAN LONDON
Elsevier Global Medical News

SEATTLE — Treating gastroesophageal reflux disease in children with persistent asthma improved lung function in the long term, new data show. Moreover, medical and surgical treatments appeared to work equally well.

Roughly two-thirds of nonatopic children with persistent asthma also have gastroesophageal reflux disease (GERD), and that disease appears to exacerbate the asthma, Dr. Aaron K. Kobernick said at the annual meeting of the American College of Allergy, Asthma, and Im-



Roughly two-thirds of non-atopic children with persistent asthma also have gastroesophageal reflux disease.

DR. KOBERNICK

munology. Studies of GERD treatment in this context have focused on asthma medication use and have been relatively short.

“We know that with asthma, short-term studies are just not as reliable,” Dr. Kobernick said. “Because asthma is a disease of exacerbation and remission, the longer we look at asthma and outcomes in asthma, the better off we are going to be.”

In a prospective 2-year study, Dr. Kobernick and his colleagues enrolled 62 children between the ages of 6 and 11 years who had moderate persistent asthma but did not have atopy or risk factors for wheezing. At baseline, all of the children underwent spirometry and extended esophageal pH monitoring. The latter testing revealed that the majority of the children also had GERD.

Of the children with asthma and GERD, 32 were treated with medical therapy for GERD consisting of proton pump inhibitors and prokinetic agents and 12 underwent surgical fundoplication; they also received asthma therapy. The 18 children who did not have comorbid GERD received asthma therapy only.

The three groups were similar with respect to age, sex, socioeconomic status, duration of illness, and initial spirometry findings, according to Dr. Kobernick, a medicine and pediatrics resident at Tulane University in New Orleans.

After 2 years of treatment, the average

annual number of asthma exacerbations per child was significantly lower, by about 75%, among both the children with medically treated GERD (0.68) and the children with surgically treated GERD (0.79), compared with their GERD-free counterparts treated for asthma alone (2.9), Dr. Kobernick reported. The difference between the medically and surgically treated GERD groups was not significant.

The percentage of children who had

an improvement in forced expiratory volume in 1 second (FEV₁) by more than 20% from baseline was significantly greater in the groups given medical GERD treatment (47%) and surgical GERD treatment (58%), compared with the group given asthma therapy alone (28%).

Similarly, the percentage of children having an improvement in forced expiratory flow in mid-expiration (FEF_{25%-75%}) by more than 20% from baseline

was significantly greater with added medical GERD treatment (22%) and surgical GERD treatment (25%), compared with asthma therapy alone (11%).

Dr. Kobernick concluded that the results may underestimate the benefit of anti-GERD treatment, because many children had been previously treated for asthma.

Dr. Kobernick reported that he had no conflicts of interest in association with the study. ■

BRIEF SUMMARY
Please see package insert for full prescribing information.

Azactam
aztreonam IM/IV 1g/2g

INDICATIONS AND USAGE: To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM® (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Before initiating treatment with AZACTAM, appropriate specimens should be obtained for isolation of the causative organism(s) and for determination of susceptibility to aztreonam. Treatment with AZACTAM may be started empirically before results of the susceptibility testing are available; subsequently, appropriate antibiotic therapy should be continued.

AZACTAM is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms:

Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Enterobacter cloacae*, *Klebsiella oxytoca*, *Citrobacter* species* and *Serratia marcescens*.*

Lower Respiratory Tract Infections, including pneumonia and bronchitis caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Proteus mirabilis*, *Enterobacter* species and *Serratia marcescens*.*

Septicemia caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, *Serratia marcescens** and *Enterobacter* species.

Skin and Skin-Structure Infections, including those associated with postoperative wounds, ulcers and burns caused by *Escherichia coli*, *Proteus mirabilis*, *Serratia marcescens*, *Enterobacter* species, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and *Citrobacter* species.*

Intra-abdominal Infections, including peritonitis caused by *Escherichia coli*, *Klebsiella* species including *K. pneumoniae*, *Enterobacter* species including *E. cloacae**, *Pseudomonas aeruginosa*, *Citrobacter* species* including *C. freundii** and *Serratia* species* including *S. marcescens*.*

Gynecologic Infections, including endometritis and pelvic cellulitis caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter* species* including *E. cloacae** and *Proteus mirabilis*.*

AZACTAM is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces. AZACTAM is effective against most of the commonly encountered gram-negative aerobic pathogens seen in general surgery.

Concurrent Therapy: Concurrent initial therapy with other antimicrobial agents and AZACTAM is recommended before the causative organism(s) is known in seriously ill patients who are also at risk of having an infection due to gram-positive aerobic pathogens. If anaerobic organisms are also suspected as etiologic agents, therapy should be initiated using an anti-anaerobic agent concurrently with AZACTAM (see **DOSAGE AND ADMINISTRATION**). Certain antibiotics (e.g., cefoxitin, imipenem) may induce high levels of beta-lactamase *in vitro* in some gram-negative aerobes such as *Enterobacter* and *Pseudomonas* species, resulting in antagonism to many beta-lactam antibiotics including aztreonam. These *in vitro* findings suggest that such beta-lactamase inducing antibiotics not be used concurrently with aztreonam. Following identification and susceptibility testing of the causative organism(s), appropriate antibiotic therapy should be continued.

CONTRAINDICATIONS: This preparation is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.

WARNINGS: Both animal and human data suggest that AZACTAM is rarely cross-reactive with other beta-lactam antibiotics and weakly immunogenic. Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure. (See **CONTRAINDICATIONS**.)

Careful inquiry should be made to determine whether the patient has any history of hypersensitivity reactions to any allergens.

While cross-reactivity of aztreonam with other beta-lactam antibiotics is rare, this drug should be administered with caution to any patient with a history of hypersensitivity to beta-lactams (e.g., penicillins, cephalosporins, and/or carbapenems). Treatment with aztreonam can result in hypersensitivity reactions in patients with or without prior exposure to aztreonam. If an allergic reaction to aztreonam occurs, discontinue the drug and institute supportive treatment as appropriate (e.g., maintenance of ventilation, pressor amines, antihistamines, corticosteroids). Serious hypersensitivity reactions may require epinephrine and other emergency measures. (See **ADVERSE REACTIONS**.)

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including AZACTAM and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*. *C. difficile* produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

Rare cases of toxic epidermal necrolysis have been reported in association with aztreonam in patients undergoing bone marrow transplant with multiple risk factors including sepsis, radiation therapy and other concomitantly administered drugs associated with toxic epidermal necrolysis.

PRECAUTIONS: General: In patients with impaired hepatic or renal function, appropriate monitoring is recommended during therapy.

If an aminoglycoside is used concurrently with aztreonam, especially if high dosages of the former are used or if therapy is prolonged, renal function should be monitored because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics.

The use of antibiotics may promote the overgrowth of nonsusceptible organisms, including gram-positive organisms (*Staphylococcus aureus* and *Streptococcus faecalis*) and fungi. Should superinfection occur during therapy, appropriate measures should be taken.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity studies in animals have not been performed.

Genetic toxicology studies performed *in vivo* and *in vitro* with aztreonam in several standard laboratory models revealed no evidence of mutagenic potential at the chromosomal or gene level.

Two-generation reproduction studies in rats at daily doses up to 20 times the maximum recommended human dose, prior to and during gestation and lactation, revealed no evidence of impaired fertility. There was a slightly reduced survival rate during the lactation period in the offspring of rats that received the highest dosage, but not in offspring of rats that received five times the maximum recommended human dose.

Pregnancy: Pregnancy Category B: Aztreonam crosses the placenta and enters the fetal circulation.

Studies in pregnant rats and rabbits, with daily doses up to 15 and 5 times, respectively, the maximum recommended human dose, revealed no evidence of embryo- or fetotoxicity or teratogenicity. No drug induced changes were seen in any of the maternal, fetal, or neonatal parameters that were monitored in rats receiving 15 times the maximum recommended human dose of aztreonam during late gestation and lactation.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, aztreonam should be used during pregnancy only if clearly needed.

Nursing Mothers: Aztreonam is excreted in human milk in concentrations that are less than 1 percent of concentrations determined in simultaneously obtained maternal serum; consideration should be given to temporary discontinuation of nursing and use of formula feedings.

Pediatric Use: The safety and effectiveness of intravenous AZACTAM (aztreonam for injection, USP) have been established in the age groups 9 months to 16 years. Use of AZACTAM in these age groups is supported by evidence from adequate and well-controlled studies of AZACTAM in adults with additional efficacy, safety, and pharmacokinetic data from non-comparative clinical studies in pediatric patients. Sufficient data are not available for pediatric patients under 9 months of age or for the following treatment indications/pathogens: septicemia and skin and skin-structure infections (where the skin infection is believed or known to be due to *H. influenzae* type b). In pediatric patients with cystic fibrosis, higher doses of AZACTAM may be warranted. (See **CLINICAL PHARMACOLOGY, DOSAGE AND ADMINISTRATION**, and **CLINICAL STUDIES**.)

Geriatric Use: Clinical studies of AZACTAM did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.⁷⁻¹⁰ In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Because elderly patients are more likely to have decreased renal function, renal function should be monitored and dosage adjustments made accordingly (see **DOSAGE AND ADMINISTRATION: Renal Impairment in Adult Patients and Dosage in the Elderly**).

ADVERSE REACTIONS: Local reactions such as phlebitis/thrombophlebitis following IV administration, and discomfort/swelling at the injection site following IM administration occurred at rates of approximately 1.9 percent and 2.4 percent, respectively.

Systemic reactions (considered to be related to therapy or of uncertain etiology) occurring at an incidence of 1 to 1.3 percent include diarrhea, nausea and/or vomiting, and rash. Reactions occurring at an incidence of less than 1 percent are listed within each body system in order of decreasing severity:

- Hypersensitivity*—anaphylaxis, angioedema, bronchospasm
- Hematologic*—pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis
- Gastrointestinal*—abdominal cramps; rare cases of *C. difficile*-associated diarrhea, including pseudomembranous colitis, or gastrointestinal bleeding have been reported. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment. (See **WARNINGS**.)
- Dermatologic*—toxic epidermal necrolysis (see **WARNINGS**), purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis
- Cardiovascular*—hypotension, transient ECG changes (ventricular bigeminy and PVC), flushing
- Respiratory*—wheezing, dyspnea, chest pain
- Hepatobiliary*—hepatitis, jaundice
- Nervous System*—seizure, confusion, vertigo, paresthesia, insomnia, dizziness
- Musculoskeletal*—muscular aches
- Special Senses*—tinnitus, diplopia, mouth ulcer, altered taste, numb tongue, sneezing, nasal congestion, halitosis
- Other*—vaginal candidiasis, vaginitis, breast tenderness
- Body as a Whole*—weakness, headache, fever, malaise

Pediatric Adverse Reactions: Of the 612 pediatric patients who were treated with AZACTAM in clinical trials, less than 1% required discontinuation of therapy due to adverse events. The following systemic adverse events, regardless of drug relationship, occurred in at least 1% of treated patients in domestic clinical trials: rash (4.3%), diarrhea (1.4%), and fever (1.0%). These adverse events were comparable to those observed in adult clinical trials.

In 343 pediatric patients receiving intravenous therapy, the following local reactions were noted: pain (12%), erythema (2.9%), induration (0.9%), and phlebitis (2.1%). In the US patient population, pain occurred in 1.5% of patients, while each of the remaining three local reactions had an incidence of 0.5%.

The following laboratory adverse events, regardless of drug relationship, occurred in at least 1% of treated patients: increased eosinophils (6.3%), increased platelets (3.6%), neutropenia (3.2%), increased AST (3.8%), increased ALT (6.5%), and increased serum creatinine (5.8%).

In US pediatric clinical trials, neutropenia (absolute neutrophil count less than 1000/mm³) occurred in 11.3% of patients (8/71) younger than 2 years receiving 30 mg/kg q6h. AST and ALT elevations to greater than 3 times the upper limit of normal were noted in 15–20% of patients aged 2 years or above receiving 50 mg/kg q6h. The increased frequency of these reported laboratory adverse events may be due to either increased severity of illness treated or higher doses of AZACTAM administered.

Adverse Laboratory Changes: Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were:

- Hepatic*—elevations of AST (SGOT), ALT (SGPT), and alkaline phosphatase; signs or symptoms of hepatobiliary dysfunction occurred in less than 1 percent of recipients (see above).
- Hematologic*—increases in prothrombin and partial thromboplastin times, positive Coombs' test.
- Renal*—increases in serum creatinine.

OVERDOSAGE: If necessary, aztreonam may be cleared from the serum by hemodialysis and/or peritoneal dialysis.

*Efficacy for this organism in this organ system was studied in fewer than ten infections.

AZACTAM is a trademark of Elan Pharmaceuticals, Inc.

Manufactured by
Bristol-Myers Squibb Company
Princeton, NJ 08543 U.S.A.

Printed in USA
E1-B001A-10-00

Revised June 2008
AZL001B00-B/J4-671A



Distributed by Elan Pharmaceuticals, Inc. (EPI). AZACTAM is a trademark of Elan Pharmaceuticals, Inc and licensed exclusively in the U.S. to EPI.

INDEX OF ADVERTISERS

Bryan Corporation	
Sclerosol	7
Elan Pharmaceuticals, Inc.	
Azactam	15-16
Sepracor, Inc.	
Brovana	10-12



The power of negative thinking

*In treatment of gram-negative infections caused
by susceptible gram-negative microorganisms*

AZACTAM is indicated for

- Complicated and uncomplicated urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections
- Adjunctive therapy to surgery in the management of infections caused by susceptible organisms. Effective against most commonly encountered gram-negative aerobic pathogens seen in general surgery

Important Safety Information: AZACTAM is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.

While cross reactivity of aztreonam with other beta-lactam antibiotics is rare, this drug should be administered with caution to any patient with a history of hypersensitivity to beta-lactams.

Clostridium difficile-associated diarrhea (CDAD) occurs with use of nearly all antibacterial agents, including AZACTAM, and severity ranges from mild diarrhea to fatal colitis. Antibacterial agent use alters the normal flora of the colon leading to overgrowth of *C difficile*. Consider CDAD in all patients presenting with diarrhea following antibiotic use. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C difficile* may need to be discontinued.

In patients with impaired hepatic or renal function, appropriate monitoring is recommended during therapy.

Please see brief summary of prescribing information on adjacent page.

think negative.



© 2008 Elan Pharmaceuticals, Inc. AZL1470608

Azactam[®]
aztreonam IV/IM 1g/2g